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A. represents normal placentation and B. illustrates events leading to abnormal 
placentation, its consequences on the maternal blood vessels and blood flow.  In 
normal placental development, cytotrophoblasts originating from the anchoring 
villi  invade the maternal spiral arteries  ensuring its dilation for maximum blood 
supply to the foetus 
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The role of Natural Killer (NK) cells in pregnancy progression post implantation is 
inconclusive. NK cells render the maternal immune system more tolerant towards the growing 
fetus, yet their extensive activation may also result in failed pregnancies. CD69 surface 
glycoprotein is an early specific marker for activated NK cell. The aim of the study was to 
determine the role of CD69-expressing NK cells in HIV-associated PE in Black South African 
women. This was done in an attempt to investigate potential techniques that may be used for 
early diagnosis of PE prior to the manifestation of clinical symptoms. The correlation between 
PE and presence of HIV in women will also be determined.   
 
Following institutional ethical approval and informed consent, clinical characteristics and 4 
Milliliters (ml) venous blood were collected each patient. Study consisted of 102 pre-
eclamptic and 58 normotensive pregnant women recruited at Prince Mshiyeni Memorial 
Hospital, a regional hospital in the eThekwini region of KwaZulu-Natal, South Africa. The 
study groups were sub-stratified according to HIV-status, while the pre-eclamptic group was 
sub-stratified according to gestational age (GA) into early-onset (EOPE) and late-onset 
(LOPE) PE. White blood cells (WBC) were extracted from the samples and then stained with 
fluorochrome-conjugated CD3, CD56, CD16 and CD69 and analysed on the multicolour flow 
cytometer. NK cells are CD3 negative, CD16 positive and CD56 positive. Results were assessed 
on the FlowJo software and exported to SPSS for statistical analysis. 
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There was no significant difference for maternal age, weight, body mass index, parity and 
gravidity based on HIV status, pregnancy type and across study groups. GA and birth weight 
differed significantly between pre-eclamptic and normotensive pregnancies, but not according 
to HIV status. Birth weight was higher in the normotensive compared to LOPE and EOPE 
group (p< 0.001). GA was lowest in the EOPE compared to normotensive and LOPE groups 
(p< 0.001).  
 
Lymphocyte count was significantly different based on HIV-status as it was higher in HIV-
positive compared to HIV-negative participants (p= 0.002). There were lower levels of 
lymphocytes in normotensive participants compared to EOPE and LOPE (p< 0.001). 
Additionally, the highest levels of lymphocytes were seen in the HIV-positive LOPE study 
group (p< 0.001). A significant difference was observed in the amount of CD3 negative 
lymphocytes (NK cells) between the HIV-positive and HIV-negative group (p= 0.011). There 
were higher levels of CD3 negative cells in the HIV-positive compared to the HIV-negative 
group. CD3 negative NK cells were higher in the pre-eclamptic compared to the normotensive 
group (p< 0.001). Additionally, this study established high levels of the CD3 negative NK cells 
in the HIV-positive EOPE study group (p< 0.001).  
 
Uterine NK (uNK) cell levels were not different according to HIV status. In contrast, 
peripheral NK (pNK) cells differed between the HIV groups (p=0.005), being higher in the 
HIV-negative compared to the HIV-positive group. Moreover, there were no significant 
differences observed between the pregnancy types and study groups with regard to both NK 
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cell subsets. There was no significant difference in the level of CD69-expressing NK cells in 
both the NK cell subgroups with respect to HIV status. With regard to pregnancy type, only 
the pNK cell subgroup showed significant difference in levels of CD69 positive cells 
irrespective of HIV status (p= 0.009). CD69 positive pNK cells were the highest in the EOPE 
group compared to the LOPE and normotensive pregnant group. 
 
The results of this study show an elevation of CD69 positive pNK cells in HIV-associated pre-
eclamptic pregnancies compared to normotensive pregnancies. This could be due to the dual 
paradigm of its immune-regulatory function or its contribution to the cytotoxic effect of NK 
cells. Moreover, with further research CD69 may be used as an early biomarker for PE 








1.1. Pre-eclampsia (PE) 
PE is a human specific disorder defined as sustained new onset of systolic blood pressure 
≥140 Millimeters of mercury (mmHg) and diastolic blood pressure ≥90 mmHg at least 4 hours 
apart, and proteinuria after 20 weeks’ gestation in a previously normotensive patient (Moodley 
2013).  Proteinuria is defined as urine dipstick protein of 1+ or more (on at least two 
occasions) or a 24 hour urine protein of at least 300 Milligrams (mg) (Powe, Levine et al. 
2011, Moodley 2013).  The exact aetiology of PE remains elusive. PE remains a vital area of 
research due too the devastatingly high maternal and neonatal morbidity and mortality 
statistics.  
 
PE may be described as a disorder emerging first from poor placentation and then presenting 
itself as a multi-system maternal syndrome (Powe, Levine et al. 2011, Walker 2011). Delivery 
of the placenta results in resolution of the disorder hence most of the aetiology of this disease 
lies within the placenta (Steegers, von Dadelszen et al. 2010). PE presents with various 
clinical features and does not manifest itself uniformly, making it difficult to diagnose and 




PE has a wide clinical spectrum and in most circumstances presents as a mild disease with few 
clinical signs (Young, Levine et al. 2010, Trogstad, Magnus et al. 2011). In severe cases of PE 
women may develop headaches or visual changes, pain in the upper abdomen arising from 
acute liver injury, pulmonary oedema, acute renal failure, haemolysis and/or 
thrombocytopenia (Young, Levine et al. 2010). PE mostly affects systemic blood vessels, and 
in this way may be seen affecting the functioning of critical organs including the liver and 
brain. The effects of this disease may be seen long after pregnancy.   
 
Immune maladaptation has been largely associated with the pathogenesis of this syndrome. 
This study examines activated pNK cells, a vital component of the innate immune system. It 
aims to investigate the involvement of pNK cells in pathological pregnancies, an area of 
research that has not been fully explored. The information produced will contribute towards 
understanding immune maladaptation in PE. 
 
1.1.1. PE epidemiology 
Globally, approximately 2-8% of pregnant women develop PE (Ghulmiyyah and Sibai 2012, 
Rebelo, Schlüssel et al. 2013). Most of PE diagnoses occur in developing countries like South 
African (see figure 1.1). PE is considered the most commonly encountered medical 
complication during pregnancy, and is also associated with increased morbidity in both mother 




In 2010, PE was reported to be the third leading cause of maternal deaths in USA accounting 
for about 16-20% maternal deaths (Young, Levine et al. 2010, Ghulmiyyah and Sibai 2012). 
In South Africa, the latest Confidential Enquiries into Maternal Deaths between 2011-2013 
reports that non-pregnancy related infections, obstetric haemorrhage and hypertension 
accounts for above 65% of maternal deaths (Pattinson 2014). Moreover, most of the maternal 
deaths arising from hypertension are directly linked to PE.  
 
The Millennium Development Goal recommended an attainment of 38 deaths per 100 000 live 
births by the year 2015.  Currently, South Africa has 310 deaths per 100 000 live births.  This 
is unacceptably high as similar low to middle income countries like Brazil have 70 deaths per 
100 000 deliveries.  Problems in accessing professional medical care and late prenatal care are 
the main reasons for the high number of maternal and neonatal mortality and morbidity in 
South Africa (Young, Levine et al. 2010, Hall, Gebhardt et al. 2013). Many lower income 
countries have poor resource settings and there is a lack of patient education on this disorder 
compared to high income countries (Steegers, von Dadelszen et al. 2010, Powe, Levine et al. 
2011). Additionally, the incident of new cases of PE are increasing globally  due to an 
increased prevalence of predisposing disorders such as chronic hypertension, diabetes, and 





Figure 1.1: Distribution of incidences of pre-eclampsia in the world. (http://cureresearch.com/pre-eclampsia/ 
Accessed on the 15 March 2016)   
 
1.1.2. PE classification 
 PE can either be classified as early-onset PE (EOPE) or late-onset PE (LOPE) 
depending on when PE developed during pregnancy. EOPE usually develops before 34 
weeks of gestation, while LOPE develops at or after 34 weeks of gestation (Li, Chen et 
al. 2014). EOPE affects about 5-20% while LOPE affects about 80% of pregnant 
women (Huppertz 2008). EOPE is regarded as a foetal disorder defined by placental 
dysfunction and more adverse maternal and neonatal outcomes, while LOPE is 
considered to be a maternal disorder resulting from underlying maternal disorders 
(Raymond and Peterson 2011). 
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 PE can also be classified as a mild, moderate or severe depending on the severity of the 
clinical characteristics. Mild and moderate PE occurs in most of the women who 
develops the disorder. 
Severe PE may also occur in variant forms in different women. One form of severe PE 
is the haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, which 
occurs in about 20% of women with severe PE (Young, Levine et al. 2010, Powe, 
Levine et al. 2011). The HELLP syndrome affects the liver function and the 
coagulation system, where some of the women may develop disseminated 
intravascular coagulation which is dangerous for both mother and foetus (Young, 
Levine et al. 2010, Powe, Levine et al. 2011). Another form of severe PE is eclampsia, 
this is a type of severe PE characterised by the occurrence of convulsions (Ghulmiyyah 
and Sibai 2012). Eclampsia has a high mortality rate for both the mother and the 
foetus, and is seen to have a higher incident rate of about 10-30 times in developing 
countries than in high income countries (Steegers, von Dadelszen et al. 2010, 
Ghulmiyyah and Sibai 2012). Most of the deaths seen in eclampsia are due to 
cerebrovascular complications and other complications of the blood vessels (Powe, 
Levine et al. 2011). Furthermore, severe PE is a major cause of profound maternal 
morbidity including stroke, renal failure and liver rupture (Powe, Levine et al. 2011, 
Walker 2011). Severe PE is also detrimental to the growing foetus and may cause 
adverse perinatal outcomes such as prematurity and intrauterine growth restriction 
(Powe, Levine et al. 2011, Walker 2011). 
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1.1.3. Risk factors 
The actual aetiology of PE is unknown, yet various factors have been implicated in increasing 
the risk of its development:  
 Geographical altitude- PE rates are higher in women living in higher altitudes because 
of the lower atmospheric oxygen content, introducing hypoxic conditions (Powe, 
Levine et al. 2011). Placental development and the functionality of the placenta are 
affected by these hypoxic conditions, predisposing the women to a higher risk of 
developing PE (Powe, Levine et al. 2011).  
 History of PE- A personal or family history of PE significantly increases the risk of PE 
development (Steegers, von Dadelszen et al. 2010). 
 First pregnancy- The risk of developing PE is as high as 7.5% during the first 
pregnancy. This has led to classifying PE as a disorder of nulliparous women (Young, 
Levine et al. 2010). 
 Parity- Primiparity is the cardinal risk factor for PE development. With multiparous 
women, the risk of developing the disease in following pregnancies is greater if the 
disease was seen early in their previous pregnancy (Trogstad, Magnus et al. 2011, 
Nawaz, Sultan et al. 2014). 
 New paternity-  PE is also associated with multiparous women especially those with a 
new partner, due to a limited exposure to the new paternal antigens (Basso, 
Christensen et al. 2001). 
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  Maternal age- Most studies have shown that PE is most highly seen in very young 
(<18 years) and very old women (>40 years) of child barring age (Cleary-Goldman, 
Malone et al. 2005). 
 Obesity- The risk of PE is higher in obese women compared to women with normal 
weight (Trogstad, Magnus et al. 2011). 
 Multiple pregnancy- PE is more common in women who are carrying twins, triplets or 
other multiples. Increased placental mass, mole development within the uterus and a 
multifetal pregnancy are seen as a threat resulting in increased risk of developing this 
condition (Duckitt and Harrington 2005). 
 Interval between pregnancies- Having babies less than two years or more than 10 years 
apart leads to a higher risk of PE development (Skjærven, Wilcox et al. 2002). 
 History of metabolic conditions- Conditions such as chronic high blood pressure, 
cardiovascular diseases, migraine headaches, type 1 or type 2 diabetes, kidney disease, 
a tendency to develop blood clots, or systemic lupus erythematosus increases the risk 
of PE development (Duckitt and Harrington 2005, Steegers, von Dadelszen et al. 2010) 
 Use of contraceptives during sexual intercourse is also seen as a pre-disposing factor in 
the development of PE (Powe, Levine et al. 2011).  
 Hormonal factors- Circulation of a higher or lower amount of hormones needed for the 
progression of pregnancy have been associated with increased risk of PE development. 
Various hormones involved in the dilation of blood vessels are lowered in pre-
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eclamptic women, causing vasoconstriction and restricting placental perfusion (Lam, 
Lim et al. 2005).  
 Smoking- In a study done by England et al (2002) smoking was labelled as a 
protective mechanism against PE development. This fact can be intensively debated as 
smoking may indirectly increase the risk of the woman acquiring predisposing 
disorders of PE like cardiovascular diseases. 
 Ethnicity- Some ethnic groups and communities of low socioeconomic status are at a 
higher risk of developing PE (Steegers, von Dadelszen et al. 2010, Ghulmiyyah and 
Sibai 2012). 
 Nutritional factors- Some dietary preferences may make the mother more susceptible 





Figure 1.2: A. represents events leading to normal placentation and B. illustrates events leading to abnormal 
placentation, its consequences on the maternal blood vessels and blood flow. In normal placental development, 
cytotrophoblasts originating from the anchoring villi  invade the maternal spiral arteries  ensuring its dilation for 
maximum blood supply to the foetus (Naicker, Khedun et al. 2003, Lam, Lim et al. 2005). 
 
1.1.4. Pathogenesis of PE 
 
1.1.4.1. Abnormal placentation 
The key purpose of the placenta is the transfer of nutrients and vital gases to the developing 
foetus, and also to eliminate waste from the foetus through the mother’s blood supply. Based 
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on this, it is seen that the placenta plays an important role in the success of the pregnancy 
(Mosimann, Wagner et al. 2013). Evaluation of the placenta from women with mild and 
severe PE have revealed several abnormalities within the placenta, including infarcts, 
prolonged inflammation, atherosclerosis and blood clots (Powe, Levine et al. 2011). 
 
In normal pregnancy, trophoblast cells migrate from the tips of the anchoring villi, passing 
through the decidua and the inner myometrium in a set timed sequence (Lam, Lim et al. 2005). 
Congruently, extra villous trophoblast cells invade the maternal spiral arterioles and remodel 
them into large-capacitance, low-resistance vessels (Naicker, Khedun et al. 2003, Trogstad, 
Magnus et al. 2011). The muscular wall of the artery is replaced with a fibroid type material in 
which are embedded trophoblast cells. Additionally the  endothelial phenotype changes 
(Naicker, Khedun et al. 2003, Ghulmiyyah and Sibai 2012). This conversion is referred to as a 
physiological change, ensuring a four-fold blood supply to the growing foetus (Naicker, 
Khedun et al. 2003). 
 
In PE, trophoblast migration of spiral arteries is limited to the decidua.  There is no 
physiological conversion of spiral arteries within the myometrium, and the cytotrophoblasts 
fails to adopt an invasive endothelial phenotype (Naicker, Khedun et al. 2003). This results in 
failure for the lumen of the arteries to modify into large calibre arteries (Moodley 2013). This 
lack of physiological transformation does not ensure maximal blood supply to and from the 
baby. The lack of oxygen supplied to the placenta creates a hypoxic environment with 
resultant oxidative stress and a release of various anti-angiogenic factors (Moodley 2013).  
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1.1.4.2. Angiogenic imbalance 
Blood vessels are vital in the succession of pregnancy, as these are the main network between 
the maternal system and the growing foetus (Shibuya 2008). For the foetus to survive; 
nutrients, oxygen and other compounds have to be transported between the maternal system 
and the growing foetus through the blood vessels (Shibuya 2008, Wang, Rana et al. 2009).  
 
In PE, the hypoxic microenvironment causes the placenta to release high levels of anti-
angiogenic factors and low levels of pro-angiogenic factors, thus disrupting the maternal 
endothelium (Young, Levine et al. 2010). The reason for the modification from the usual 
angiogenic stability into an anti-angiogenic state may be linked to the oxidative stress arising 
from the ischaemic conditions (Young, Levine et al. 2010). This shift is said to be the main 
cause of the maternal hypertensive syndrome, proteinuria as well as other clinical signs of PE 
and eclampsia (Lam, Lim et al. 2005, Young, Levine et al. 2010). 
 
Various angiogenic factors and cytokines play a vital role during blood vessel formation 
(angiogenesis) and maintenance. Angiogenic factors and cytokines that are important for the 
formation and maintenance of blood vessels in pregnancy include: Vascular Endothelial 
Growth Factor (VEGF), Endocrine Gland derived Vascular Endothelial Growth Factor (EG-
VEGF), Transforming Growth Factor-β (TGF- β) and Placental Growth Factor (PlGF). These 
factors and cytokines are pro-angiogenic and will support the formation of blood vessels 
during pregnancy. Deficiency and improper balance between these angiogenic factors has 
detrimental effects on the progression of pregnancy (Naicker, Khedun et al. 2003, Wang, Rana 
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et al. 2009, Powe, Levine et al. 2011). Prior studies have also shown that in diseased states the 
placenta releases excessive amount of anti-angiogenic factors into the maternal blood resulting 
in the distinctive characteristics of PE both locally and systemically (Young, Levine et al. 
2010). Anti-angiogenic factors that are released during PE include: endothelin-1, fibronectin, 
soluble endoglin (sEng), and soluble fms-like tyrosine kinase-1 (sFlt-1). During PE these anti-
angiogenic factors inhibit the action of pro-angiogenic factors by binding to them, preventing 
the binding of pro-angiogenic binding to endothelium receptors like endoglin receptors (ENG) 
TGF- β receptors (Alk5) (see figure 1.3). 
   
a) Vascular endothelial growth factors (VEGF)  
VEGF is a pro-angiogenic factor involved in the formation of new blood vessels in the embryo 
and the placenta for the advancement of pregnancy (Shibuya 2008, Powe, Levine et al. 2011). 
VEGF also plays an important role in established blood vessels and tissues of other organs to 
maintain efficient blood flow (Lam, Lim et al. 2005, Powe, Levine et al. 2011). VEGF is 
involved in the succession of endothelial cells and in making endothelial cells more permeable 
(Wang, Rana et al. 2009). In some organs, for example the kidney and heart, VEGF may have 
vasodilator effects involving it in the control of the systemic blood pressure thus the control of 
hypertension (Powe, Levine et al. 2011). The incorrect expression or/and deletion of the gene 
responsible for VEGF production may cause death of the foetus at the embryonic phase 
(Shibuya 2008, Wang, Rana et al. 2009). This may be due to irregular formation of blood 
vessels in both embryo and placenta in the early stages of pregnancy. In the maternal body, 
VEGF irregularities affect multiple organs including the brain, liver and kidney (Powe, Levine 
et al. 2011).  
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VEGFs bind to receptors present on vascular endothelial cells to modulate and regulate the 
endothelial cells (Figure 1.2) (Shibuya 2008). The binding of VEGFs to endothelial cells 
maintains their integrity and wellbeing and facilitates the relaxation of blood vessels, 
preventing both the proteinuria and hypertension (Wang, Rana et al. 2009). In some organs 
like the kidney, VEGFs are involved in maintaining the fenestrated nature of endothelial cells 
(Lam, Lim et al. 2005). Presence of abnormal VEGF molecules in the kidney affect the 
fenestrated nature of the endothelial cells, making them incapable to perform their function of 
preventing large molecules like proteins to filter through into the urine. Therefore, imbalance 
of the expression of pro-angiogenic and antiangiogenic factors also plays an important role in 
the development of proteinuria, which is an important characteristic in diagnosing PE (Wang, 
Rana et al. 2009, Powe, Levine et al. 2011).  
 
b) Transforming Growth Factor- β (TGF-β) 
TGF-β plays different roles in different tissues and is not fully understood in its functions. In 
angiogenesis, absence of TGF-β and its isoforms have harmful effects on the development of 
new blood vessels in both the embryo and placenta, and in most to all cases results in the death 
of the foetus (Wang, Rana et al. 2009, Powe, Levine et al. 2011). Most studies have also 
implicated TGF-β in the trans-signalling regulation of VEGF, moreover indicating its 
importance in angiogenesis (Wang, Rana et al. 2009, Powe, Levine et al. 2011). In mature and 
newly formed blood vessels, the facilitated binding of TGF-β is involved in the homeostasis 




c) Placental Growth Factor (PlGF) 
During pregnancy the placenta also releases PlGF (Lam, Lim et al. 2005). Absence of PlGF is 
seen to have no adverse effects on the maternal body (Powe, Levine et al. 2011). In instances 
like myocardial infarction and wound healing absence of PlGF may have detrimental effects, 
suggesting that this growth factor is important for angiogenesis in the pathological conditions 
(Wang, Rana et al. 2009). In pregnancies without any complications the function of PlGF is 
not fully understood. 
 
 
Figure 1.3: The role of angiogenic factors in normotensive pregnancies and in pre-eclamptic pregnancies (Powe, 




1.1.5. Clinical features of PE 
PE is very complicated in its manifestation and diagnosis. Hypertension and proteinuria are at 
a diagnostic level in pregnancy when systolic blood pressure is ≥140 mmHg, diastolic blood 
pressure is ≥90 mmHg and there is ≥300 mg of proteins in a 24 hour urine specimen (Young, 
Levine et al. 2010, Moodley 2013). In the absence of one or both of the clinical features, 
laboratory testing of organ functionality may be used to diagnose existence of PE in pregnant 
women (Powe, Levine et al. 2011). Traditionally oedema was also used as a diagnostic triad of 
PE. This was found to be problematic as most normotensive women also present with oedema 
during their pregnancy, this is as oedema is not only specific to pre-eclamptic patients (Young, 
Levine et al. 2010). Presentation of glomerular endotheliosis and HELLP in pregnant women 
may also be seen as a sign of the existence of PE (Young, Levine et al. 2010, Powe, Levine et 
al. 2011). Another clinical feature that has been associated with PE is podocyturia, this is the 
shedding of viable amounts of podocytes in urea (Powe, Levine et al. 2011).  
 
1.1.6. Management of PE 
A pharmaceutical cure for the disease has not been developed to date, and administration of 
therapeutics/drugs to pregnant women may be associated with teratogenic effects on the 
neonate. Early detection of the clinical characteristic of PE (hypertension and proteinuria), 
delivery of the placenta, and management of the hypertension through maternal diet and 
exercise still remain the fundamental approach to resolve the disease and prevent serious 




A decision of induced premature delivery is mostly used in developed countries to protect the 
health of the mother (Young, Levine et al. 2010, Powe, Levine et al. 2011). Yet, the method of 
premature delivery has shown to have adverse results in the survival of the neonate and may 
result in low birth weight, morbidity and mortality (Young, Levine et al. 2010, Powe, Levine 
et al. 2011). This may be due to inadequate development of the foetus as it has not reached its 
full developmental ability. 
 
The lack of medications to treat PE requires that the foetus is closely monitored using 
ultrasound examination and foetal heart rate testing to ensure the survival of the foetus 
(Young, Levine et al. 2010). The maternal blood pressure, heart rate and urine protein are 
closely supervised to ensure that the disease does not manifest into any other conditions that 
may be fatal to the mother or the foetus (Steegers, von Dadelszen et al. 2010, Powe, Levine et 
al. 2011). It is advisable to monitor both mother and child post-delivery to prevent 
complications, morbidity and mortality (Moodley 2013). In the case of eclampsia, doctors are 
forced to administer treatments that may be detrimental to the foetus due to the severe 
implications of this condition. Pregnant women who are eclamptic are given magnesium 
sulfate prophylaxis to seize the occurrence of convulsions (Powe, Levine et al. 2011). 
 
The clinical symptoms of PE are seen only after 20 weeks of gestation. This fact brings about 
a need to use other methods of diagnosis, thus assisting in the management of the disorder. 
Biological molecules have been proposed as early biomarkers for PE, these are seen to be 
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elevated in pre-eclamptic pregnancies before the onset of clinical indicators. Biological 
molecules that have been proposed include:  
1) CD69 receptor: an early specific marker for activated NK cells (Lund, Boysen et al. 
2012). 
2) Lipid concentrations and C-reactive protein: inflammatory cytokines that are increased 
in over weight and obese women (Rebelo, Schlüssel et al. 2013). 
3) Long pentraxin receptor: a soluble pattern recognition receptor that is up-regulated in 
inflammatory responses (Than, Romero et al. 2008).  
4) Soluble endoglin and sFlt-1: anti-angiogenic factors present in high amounts in pre-
eclamptic women (Lam, Lim et al. 2005). 
 
1.2. HIV and PE 
South Africa represents a unique and ideal site to study co-morbidities of both PE and HIV. 
Non pregnancy related female infections (predominately HIV) and hypertension 
(predominately PE) contribute to about 50% of maternal deaths in South Africa (Pattinson 
2014).  Moreover; the province of KZN, in which this study was conducted, is considered the 
epicentre of the global HIV pandemic.  
 
Data that is available on the effect of HIV infection on the progression of PE is inconsistent. 
Some studies have found that PE is less common in HIV infected women compared to the 
general population, this is linked to the lowered immune-reactivity associated with HIV 
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infection (Hall, Gebhardt et al. 2013, Kalumba, Moodley et al. 2013). In contrast, a study by 
Boyajian et al (2012) indicated that HIV-positive woman developed a more severe form of PE 
due to their dysfunctional immune system. To date, there has been no agreement between HIV 
infection and PE development and progression.  
 
1.3. Immune system in pregnancy 
In normal pregnancy a mild inflammatory response is seen due to the foreign paternal 
pathogens (Mor, Cardenas et al. 2011, Mosimann, Wagner et al. 2013). In PE the 
inflammatory response is exaggerated leading to maternal intolerance towards the pregnancy. 
This maternal intolerance is seen as one of the aetiologies of PE, associating the immune 
system to the development of PE (Steegers, von Dadelszen et al. 2010, Walker 2011).  
 
The human immune system is divided into two intercalated systems; the adaptive immune 
system and the innate immune system. The adaptive immune system is said to be the more 
specific reaction, using a larger spectrum of receptors (Castle 2000, Vivier, Raulet et al. 2011). 
It consists of the cellular and a humoral response, and is able to create memory cells that assist 
in a more rapid response upon encountering the same antigen (Castle 2000, Vivier, Raulet et 
al. 2011). The innate immune system is considered to be the less studied component, it is 
regarded to be more rapidly reactive and consists of a cellular and a non-cellular compartment 




The focus of this study is to investigate a component of the innate immune system, the NK 
cells. NK cells are an important component of the innate immune system, these cells are key 
players as the first defence against viral infections and tumour development  (Vacca, Moretta 
et al. 2011, Vivier, Raulet et al. 2011). NK cells also play a crucial role in development of 
normal pregnancy (Vacca, Moretta et al. 2011). The function of NK cells in pregnancy have 
been extensively debated among researchers. On one hand, NK cells are supportive in the 
progression of normal pregnancy. Alternatively, increased activated NK cell counts may 
contribute to increased foetal and maternal deaths as well as failed in vitro fertilization 
attempts (Thum, Bhaskaran et al. 2004, Mosimann, Wagner et al. 2013). This is as the 
activated NK cells may recognize the paternal antigens as foreign harmful materials and 
activate an inflammatory response.  
 
1.3.1. Cytokines involved in pregnancy 
For a proficient reaction of the immune system, immune cells of both the adaptive and innate 
system have to work collectively to attempt to eliminate infections.  Interaction between the 
different immune cells is accomplished by hormone-like proteins known as cytokines (Castle 
2000, Vivier, Raulet et al. 2011). Cytokine are important in promoting and/or halting the 
inflammation response, and are available in varying biochemical structures (Lund, Boysen et 
al. 2012). These proteins play an important role in the immune system, and are specific in their 




During pregnancy there is production of a variety of cytokines which supports the progression 
of the pregnancy. In a normal pregnancy, cytokines produced are said to up-regulate a T-
helper 2 (Th2) immune response, where as in pre-eclamptic pregnancies cytokines produced 
promote a  T-helper 1 (Th1) immune response (Figure 1.3) (Castle 2000). The Th1 response is 
more of an acquired immunity and utilises cell-mediated reactions to eliminate most 
pathogenic antigens (Hosono, de Boer et al. 2003). Th1 involved cytokines and interleukins 
(IL) are described as cytokines that promote the inflammatory response, these include IL-2, 
IL-12, Tumour Necrosis Factor-α and Interferon-γ (IFN-γ) (Lund, Boysen et al. 2012, Jewett, 
Man et al. 2013). The Th2 immune response is less efficient in eliminating infections, and is 
associated with a higher amount of anti-inflammatory cytokines including IL-4, IL-5, Il-10 




Figure 1.4: Different immune responses between the different pregnancy states. 
 
IL-15 and IL-2 are cytokines with overlapping properties responsible for the activation of NK 
cells (Vivier, Raulet et al. 2011, Lund, Boysen et al. 2012). IL-15 and IL-2 are responsible for 
NK cell development, survival and activation in order for the NK cells to perform their 
Normal pregnancy       Non-pregnant           Pre-eclamptic pregnancy 
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function (Vivier, Raulet et al. 2011). IL-15 is produced in multiple tissues by monocytes, 
macrophages and dendritic cells, while IL-2 is produced by activated lymphatic T-cells 
(Vacca, Moretta et al. 2011, Vivier, Raulet et al. 2011). In humans; IL-2 is seen to be more 
abundant then IL-15, performing most of the functions responsible for the activation of NK 
cells (Lund, Boysen et al. 2012). Activation of NK cells release various cytokines including 
IFN-γ and IL-8 (Vivier, Raulet et al. 2011). The release of IFN-γ and IL-8 by activated NK 
cells contribute in tissue and spiral artery remodelling as well as the formation of new blood 
vessels (Vacca, Moretta et al. 2011, Vivier, Raulet et al. 2011). 
 
During pregnancy the placenta releases various cytokines including IL-4 and IL-18 to 
modulate NK cells to lose their killing capabilities, thus assisting in the progression of 
pregnancy by protecting the paternal antigens (Roussev, Dons’koi et al. 2013). The modulated 
NK cells express properties of the uNK cells, alternatively making the population of uNK cells 
within the uterus greater. 
 
Other cytokines important for the functioning of NK cells include Intracellular Adhesion 
Molecules (ICAM) and Vascular Cellular Adhesion Molecules (VCAM). ICAMs and VCAMs 
are chemotactic factors, responsible for the migration of NK cells into tissues and secondary 
lymphoid organs (Vivier, Raulet et al. 2011). These chemotactic factors are important for 
recruiting NK cells to sites where they are needed the most. In pregnancy these chemotactic 
factors assist in the recruitment of pNK cells into the uterus to form uNK cells (Tang, 
Alfirevic et al. 2011).  
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1.3.2. NK cell sub-groups 
NK cells may be divided into two sub-groups, uterine Natural Killer (uNK) and peripheral 
Natural Killer (pNK) cells. Both these subsets of NK cells play a vital role in the success of 
pregnancy. The uNK play an important role in implantation, other placental functions and 
foetal survival necessities (Mosimann, Wagner et al. 2013). The pNK cells play an important 
role in the maternal systemic blood stream.  
 
Difference between the two sub-groups of NK cells is mostly seen in their cytotoxicity levels.  
uNK cells are said to be less cytotoxic and produce more cytokines compared to pNK cells 
(Figure 1.4) (Mosimann, Wagner et al. 2013). During pregnancy, changes in the maternal 
body are required for supporting the pregnancy, demanding a change in the systemic immune 
system (Tang, Alfirevic et al. 2011). To facilitate pregnancy uNK cells are seen to be more 
predominate in the uterus, this is to modulate the body to be more tolerant of the paternal 





Figure 1.5: Differences in uNK (CD56
Bright)
 and pNK (CD56
Dim
) cells. uNk cells show to be less cytotoxic 
compared to pNk cells considering the amount of cytokine they release and the surface glycoproteins they display 
(Cooper, Fehniger et al. 2001). 
 
1.3.3. NK cell receptors 
The receptors responsible for the activation of NK cells (activator receptors) are mainly 
Natural Cytotoxicity Receptors, Killer Immunoglobulin-like Receptors (KIR), NKG2D, CD94/ 
NKG2C, CD84, CD16 and CD69 (Figure 1.5) (Vivier, Raulet et al. 2011). Binding of specific 
antigens/cytokines to the activating receptors activates the NK cells, while binding of specific 
antigens/cytokines to inhibition receptors like CD94/NKG2A and Natural Killer Cell Receptors 
inhibits the functioning of NK cells (Figure 1.5) (Vacca, Moretta et al. 2011, Vivier, Raulet et 
al. 2011).  
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NK cells are recognized by their expression of both activator and inhibitor cell surface 
receptors (Vivier, Raulet et al. 2011, Mosimann, Wagner et al. 2013).  NK cells usually do not 
express the CD3 receptor on their cell surface, and possess both CD16 and CD56 (Mosimann, 
Wagner et al. 2013). The two subsets of NK cells, uNK and pNK cells differ in the expression 
of activation and inhibition receptors (Figure 1.4) (Vivier, Raulet et al. 2011, Mosimann, 
Wagner et al. 2013). The uNK cells lack most of the activator receptors (CD16 and CD69) and 
possess a high number of inhibitor receptors like CD56, thus they are said to be CD56
Bright 
(Figure 1.4) (Vivier, Raulet et al. 2011, Mosimann, Wagner et al. 2013). While pNK cell 
subgroup express a lot of activator receptors and low number of inhibitor receptors like CD56, 
thus they are referred to as CD56
Dim 
(Figure 1.4) (Vivier, Raulet et al. 2011, Mosimann, 
Wagner et al. 2013). Due to the difference in surface receptors, NK cell sub-groups differ in 
function. The uNK cell sub-group is more capable of perform a more protective function in the 
uterus, whilst pNK cells are more suited to perform their function in the peripheral body. 
 
The focus of this study is on the CD69 surface glycoprotein of NK cells. CD69 is one of the 
early specific markers for activated NK cells (Mosimann, Wagner et al. 2013). It is involved in 
the activation and differentiation process of NK cells and other lymphocytes (Sancho, Gómez 
et al. 2005). Expression of CD69 is triggered by various mechanisms including the presence of 
cytokines IL-2 and IL-15 (Hosono, de Boer et al. 2003, Lund, Boysen et al. 2012). CD69 is 
said to be an immune-regulatory molecule expressed by immune cells during an immune 
response and at chronic inflammation (Sancho, Gómez et al. 2003, Sancho, Gómez et al. 
2005). CD69 is therefore highly expressed on cytotoxic NK cells, indicating presence of 
inflammation. In normal pregnancy NK cells are less cytotoxic and express less activator 
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receptors on their surface, this is why uNK cells are predominate in the uterus. For this reason, 
CD69 may be used as an early biomarker for PE and other pathological inflammatory 
conditions due to its early expression on immune cells.  
 
 
Figure 1.6: Activated NK cells express various surface glycoproteins and produce a variety of cytokines (VEGF, 
IL-8, SDF1 and IP10) that go on to perform function that are necessary in placental development and the 
progression of a normal pregnancy (Vacca, Moretta et al. 2011). 
 
1.4. Hypothesis of the study 
NK cells will be investigated via their cell-surface glycoproteins to review their involvement 
in HIV-associated PE. CD69, CD3, CD56 and CD16 receptors will be the main focus of this 
study, and will be used to determine the NK cell activation status and also uNK and pNK cell 
population. The study hypothesizes that the levels of CD69-expressing NK cells will be higher 




1.5. Aims and Objectives of the study 
The study investigates two leading causes of foetal and maternal deaths in South Africa, 
mainly HIV and hypertension. South Africa is a suitable site for studying HIV-associated PE 
because statistical studies have shown that 30% of women attending the antenatal ward of 
South African clinics and hospitals are HIV-positive (Kalumba, Moodley et al. 2013). 
 
The aim of the study is to determine the role of CD69 in HIV-associated PE among black South 
African, and also to evaluate clinical characteristics associated with PE. The objectives were 
to quantify NK cells in the normotensive HIV-negative, normotensive HIV-positive, EOPE 
HIV-negative, EOPE HIV-positive, LOPE HIV-negative and LOPE HIV-positive study 







CHAPTER 2  
MATERIALS AND METHODS 
 
2.1. Study approval 
This study was conducted at the Optics & Imaging Centre, Doris Duke Medical Research 
Institute (DDMRI), University of KwaZulu-Natal (UKZN) from February 2014 to November 
2015. Approval from the Institutional postgraduate office and UKZN Biomedical Research 
Ethics Committee was obtained (Ref. no. BE 212/14; Appendix I, page 87). 
 
2.2. Patient recruitment 
Patients were recruited at the antenatal clinic and labor ward by a research midwife at Prince 
Mshiyeni Memorial Hospital, a regional hospital in the eThekwini region of KwaZulu-Natal, 
South Africa. The hospital is a 1200 bedded facility that serves the surrounding area, up to and 
including part of the Eastern Cape, South Africa.  Informed consent was obtained from all 
patients by a trained research nurse (Appendix II, page 88). Patients’ confidentiality was 
firmly maintained by keeping all information collected from the patients in a locked cupboard. 
Only personnel involved in the study had access to the cupboard. 
 
2.3. Study population 
A total of 180 patients were to be analyzed. The sample groups that were to be analyzed for 
the study are depicted in Figure 2.1. The study group included HIV-positive and HIV-
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negative, pre-eclamptic and normotensive pregnant Black South Africans. Purposeful 
sampling strategy was used based on the inclusion and exclusion criteria outlined below.  
 
Figure 2.1: Study Groups with sub-stratification based on HIV status and onset of PE development. 
 
2.4. Inclusion criteria 
The study included primigravida and multigravida pre-eclamptic (≥140/90 mmHg and at least 
1+ proteinuria on dipstick) and normotensive pregnant women. Only South African Black 
females ≥18 years were included in the study population. This sampling strategy was used to 
maintain a homogeneous population, and also because a greater percentage of woman visiting 
Prince Mshiyeni Memorial Hospital are Black South Africans. Both HIV-positive and HIV-
29 
 
negative pregnant women participated in the study. HIV status was based on standard of 
health care protocol in KZN, SA.  
 
2.5. Exclusion criteria 
The exclusion criteria comprised of patients who were not booked into the antenatal and labor 
clinic of Prince Mshiyeni Memorial Hospital, non-black South Africans, patients with 
unknown HIV status, patients who are chronically using pharmaceutical drugs (recurrent 
antibiotic or steroid usage), and those who have been diagnosed with polycystic ovarian 
syndrome, chorioamnionitis, chronic hypertension, eclampsia, diabetes, chronic renal disease, 
systemic lupus erythematosus, sickle cell disease, antiphospholipid antibody syndrome, 
thyroid disease, cardiac disease, pre-existing seizure disorder, active asthma requiring 
medication during pregnancy, and patients who have suffered from abruption placentae and 
intrauterine death during previous pregnancies. 
 
2.6. Data and blood collection methods and tools 
The research midwife collated patient clinical information onto a patient’s information sheet 
(Appendix III, page 92). Information was collected from the patient’s case notes and verbal 
interviews. Clinical variables included maternal age, height and weight; parity; gestational age 
(GA); concentration of the proteinuria; blood pressure; HIV status; obstetric and neonatal 




The research midwife also collected venous blood into a 4 ml K3EDTA anti-coagulant 
vacutainer blood collection tube (Greiner Bio-One, US). Blood samples tubes were labeled 
using a sample number unique for each patient and placed in an ice box and transported 
immediately to the Optics and Imaging Centre, DDMRI at UKZN Medical School Campus for 
multicolor flow cytometry analysis. The blood samples were analyzed within 6 hours of 
collection at K-RITH. Laboratory variables included CD3; CD16; CD56
 
and CD69 scatterplots. 
 
2.7. Flow cytometry 
 
2.7.1. Principle of flow cytometry 
Analysis of the antigen-antibody complexes were prepared using the BD LSRFortessa
TM
 
multicolor flow cytometer (Becton, Dickinson and Company, San Jose, CA 95131 USA), 
which is able to analyze eleven different fluorochromes per analysis. A flow cytometer passes 
cells (or particles) in single file through a laser beam and then analyzes the interaction of the 
laser with the individual cells. The direction change of the laser provides information on size 






Figure 2.2: Cells move through the flow cytometer and are visualized with an aid of fluorochromes, laser beams, 
filters, deflectors and light detectors found within the apparatus. The structure of the cells are then determined by 
computer analysis, this helps determine the composition of the sample being analyzed (Brown and Wittwer 
2000). 
 
2.7.2. Flow cytometry analysis 
CD3, CD16, CD56 and CD69 antibodies (Becton, Dickinson and Company, San Jose, CA 95131 
USA) were conjugated to fluorescent chemical compounds known as fluorochromes. The 
fluorochromes re-emit light upon excitation and enable visualization of the antigen-antibodies 
complex (Ormerod 2000). Conjugated antibodies were: CD3 attached to BD HV500 
fluorochrome, CD16 to FITC, CD56 to PECy7 and CD69 to BV421. The wavelengths of 
fluorochromes were selected to ovoid spectral overlap during analysis of antigens on the BD 
LSRFortessa
TM
 multicolor flow cytometer apparatus. Care was taken to avoid non-specific 




2.7.3. Optimizing antibody dilutions for flow cytometry analysis 
Six Falcon (Becton, Dickinson and Company, Franklin Lakes, NJ 07417 USA) sterile tubes 
were labeled 1 to 6. In all 6 tubes, 20 microliters (µl) of staining buffer (1x phosphate-buffered 
saline, LONZA BioWhittaker
®
, Belgium + 0.1% (w/v) sodium azide, Sigma-Aldrich
®
, Saint 
Louis, MO 63103, USA) (Appendix IV, page 98) was added followed by 10 µl of antibody 
and topped up to a final volume of 40 µl. Tube 1 was vortexed to mix the solution thoroughly 
and then 20 µl of the sample was transferred to tube 2, leaving 20 µl of sample in tube 1 and 
40 µl of sample in tube 2. The same cycle was done for tube 2 up to tube 5. In tube 5, 20 µl of 
sample was discarded after vortexing, leaving all 6 tubes with a uniform amount of sample 
(see Table 2.1). Tube 6 only contained 20 µl of staining buffer and was used as a control tube, 
therefore containing no antibody solution. In all 6 tubes, 300 µl of whole blood was added. 
The tubes were vortexed to mix the antibody-staining buffer solution with the whole blood. 
All 6 tubes were then incubated at room temperature (20° to 25°C) in the dark for 30 minutes. 
The tubes were kept in the dark as they contained a light sensitive fluorochrome conjugated 
antibody. Post incubation, 3ml of 1X BD FACS Lysis solution (Cat. No. 349202) (Appendix 
IV, page 90) was added to all six tubes; the tubes were vortexed and incubated at room 
temperature in the dark for 10 minutes. The BD FACS Lysis solution was used for lysing the 
red blood cells (RBC), as the target NK cells are only found in the white blood cell (WBC) 
layer. Tubes were then centrifuged at 1500 revolutions per minute (rpm) (at 25°C) for 5 
minutes to form a pellet of WBCs. The supernatant containing the lysed RBCs was decanted. 
The pellet was then washed twice with 3 ml of wash buffer (1x phosphate-buffered saline, 
LONZA BioWhittaker
®
, Belgium + 0.1% (w/v) sodium azide, Sigma-Aldrich
®
, Saint Louis, 
MO 63103, USA), centrifuging after every wash at 1500 rpm (at 25°C) for 5 minutes and 
discarding the supernatant after every wash. 300 µl of wash buffer was added into each tube 
33 
 
after the second wash. The tubes were stored at 2-8°C until they were analyzed. Before 
analysis all 6 tubes were vortexed thoroughly to mix the pellet with the wash buffer, tubes 
were then analyzed on the BD LSRFortessa
TM 
Flow Cytometer.  
 
Table 2.1: Volume of antibodies utilized.  
 CD3 CD16 CD56 CD69 
Tube 1 5µl of CD3 10µl of CD16 
3µl of CD3 
5µl of CD56 
3µl of CD3 
5µl of CD69 
3µl of CD3 
Tube 2 2.5µl of CD3 5µl of CD16 
3µl of CD3 
2.5µl of CD56 
3µl of CD3 
2.5µl of CD69 
3µl of CD3 
Tube 3 1.25µl of CD3 2.5µl of CD16 
3µl of CD3 
1.25µl of CD56 
3µl of CD3 
1.25µl of CD69 
3µl of CD3 
Tube 4 0.625µl of CD3 1.25µl of CD16 
3µl of CD3 
0.625µl of CD56 
3µl of CD3 
0.625µl of CD69 
3µl of CD3 
Tube 5 0.3125µl of CD3 0.625µl of CD16 
3µl of CD3 
0.3125µl of CD56 
3µl of CD3 
0.3125µl of CD69 
3µl of CD3 
Tube 6 No antibody No antibody No antibody No antibody 
 
2.7.4. Staining and lysis of whole blood 
To analyze each blood sample the optimal concentrations of the fluorochrome conjugated 
antibodies CD16, CD3, CD69 and CD56 were added to the Falcon sterile tube and the antibody 
cocktail was topped up with distilled water to 50 µl. Blood (300 µl) was then added to the 
tube, and the mixture was vortexed gently and incubated in the dark at room temperature (20° 
to 25°C) for 30 minutes to allow for adequate attachment of the antibodies to the antigens 
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present on the WBCs. Following the incubation period, 3 ml of BD FACS Lysing Solution 
was added to the tube. The tube was vortexed and incubated for 10 minutes in the dark at 
room temperature. The tube was centrifuged at 1500 rpm for 5 minutes at 25°C to form a 
pellet of WBCs at the bottom of the tube. The supernatant containing the lysed RBCs was 
decanted from the tube, and the pellet was washed twice with 3 ml of wash buffer centrifuging 
after every wash at 1500 rmp (at 25°C), and discarding the supernatant after every wash. 300 
µl of wash buffer was added to the pellet and the tube was stored at 4°C until analyzed. Before 
analysis, the tube was vortexed thoroughly to mix the pellet with the wash buffer, and the 
sample was analyzed on the BD LSRFortessa
TM
 Flow Cytometer. Results for each blood 
sample were viewed and analyzed on the BD FACSDiva (Version 7, Becton, Dickinson and 
Company. © 2015 BD) and FlowJo (Version 10) software. 
  
2.8. Data analysis techniques 
 
2.8.1. Compensation set up 
Compensation in multicolour flow cytometry is important for the accurate interpretation of 
data by making visualization of the different cell populations possible (Roederer 2001). 
Compensation set up is essential for matching antibodies to fluorochromes with colours of 
different wavelengths to prevent spill over and optimize visualization (Roederer 2001). In this 
study, the BD
TM
 CompBeads Compensation Particles Set (Anti-Mouse Ig, ĸ/Negative Control) 
(Becton, Dickinson and Company, San Diego, CA 92121, USA) was used to optimize 
fluorescence compensation settings.  
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Compensation analysis was done for CD3, CD16, CD56 and CD69 fluorochrome-conjugated 
antibodies. For the analysis; 2.5µl of CD3 antibody, 10µl of CD16 antibody, 2.5µl of CD56 
antibody, and 2.5µl of CD69 antibody was used. The BD
TM
 CompBeads were first vortexed to 
ensure that the microparticles within the sample were uniformly distributed. Four Falcon 
sterile tubes were labeled for each of the fluorochrome-conjugated antibodies. 100µl of 
staining buffer was added to all four tubes. One drop (approximately 60µl) of the BD
TM
 
CompBeads Anti-Mouse Ig,ĸ and one drop of the BD
TM
 CompBeads Negative Control were 
both added to all four tubes, the tubes were slightly vortexed. The fluorochrome-conjugated 
antibodies were then added to the respective labelled tube (one antibody per tube). The BD
TM
 
CompBeads/Antibody mixture was vortexed and incubated at room temperature in the dark for 
30 minutes. Following the incubation period, 2ml of staining buffer was added to all four 
tubes and the tubes were centrifuged at a speed 1500 rpm for 5 minutes at room temperature. 
The supernatant was discarded in all the tubes using a Pasteur pipette (LASEC, 2014), leaving 
bead pellets at the bottom of each tube. The pellets in all tubes were re-suspended in 0.5ml 
staining buffer. All tubes were vortexed thoroughly before analyzing on the BD 
LSRFortessa
TM
 Flow Cytometer.  
 
2.8.2. Fluorescence minus one (FMO) 
FMO is a control used to properly interpret flow cytometry data. The FMO control is used for 
the accurate gating of cells. FMO controls were done for CD3, CD16, CD56 and CD69 
fluorochrome-conjugated antibodies. Four Falcon sterile tubes were labeled for each of the 
fluorochrome-conjugated antibodies. In each tube the optimal concentrations of all the 
antibodies except for the antibody being tested were added (see Table 2.2). After adding the 
36 
 
antibodies, 300µl of whole blood was added to all the tubes. Tubes were then analyzed on the 
BD LSRFortessa
TM
 Flow Cytometer, and results were used for accurate gating of cells 
regarding that particular surface glycoprotein. 
 
Table 2.2: Volume of FMO controls utilized in the study. 
 Contents of the tube 
Tube 1 (FMO-CD3) 5µl CD16 
1.5µl CD56  
3µl CD69 
Tube 2 (FMO- CD16) 3 µl CD3 
1.5µl CD56 
3µl CD69 
Tube 3 (FMO- CD56) 3 µl CD3 
5µl CD16 
3µl CD69 




2.8.3. Rainbow beads 
Rainbow Beads are used for calibrating the flow cytometer apparatus before acquiring the cell 
sample. Rainbow Beads contain a combination of fluorochromes spectrally similar to the 
fluorochromes used in flow cytometry. For this study, the Sphero
TM
 Rainbow Fluorescent 
Particles (Becton, Dickinson and Company, San Diego, CA 92121, USA) that were used had a 
mid-range F1 fluorescence of 3-3.4 micrometers. 
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Before acquiring samples on the BD LSRFortessa
TM
 Flow Cytometer, a tube containing 
Rainbow Beads was first acquired to ensure that the voltages used on the BD LSRFortessa
TM
 
Flow Cytometer were accurate for the fluorochromes-conjugated antibodies analysis. The tube 
of Rainbow Beads was prepared by vortexing 3 drops of Sphero
TM
 Rainbow Fluorescent 
Particles and 300 µl of sheath fluid (Becton, Dickinson and Company BD Biosciences 2350 




 multicolor flow cytometer 
Samples from study participants were analyzed using the BD LSRFortessa
TM
 multicolor flow 
cytometer. BD FACSDiva software in collaboration with FlowJo software was used to view 
and analyze the results. FACSDiva sorts the cells according to their different characteristics, 
therefore identifying the different cells and particles available in the mixture being analyzed. 
To perform analysis of the surface glycoproteins found on NK cells the gating strategy 





Figure 2.3: A: Lymphocytes were gated in the acquired cell population. B: From the lymphocyte population the 















levels of CD69-expressing cells were determined. 
 
2.9. Statistical analysis 
SPSS (Version 22) was used to analyze patient clinical characteristics, quantity of the 
peripheral NK cells and to evaluate the difference in CD69 concentrations and levels (mean 
fluorescence intensity) in the different groups. To determine the statistical differences between 
study groups, firstly the normality of the sample distribution within the study groups was 
assessed using Shapiro–Wilk test. Based on the normality status of the data and the type of 
data to be analyzed, different statistical analyses were used to compare the proportions across 
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the study groups. Results from the flow cytometry and the statistical analysis were presented 
as tables containing significance of the results, means, standard deviations, quartiles and 
interquartile range. 
 
The independent variables of the study were HIV-status, pregnancy type and study groups 
(HIV status and pregnancy type). The independent variables were classified as binary (HIV-
status) or nominal (pregnancy type and study groups). All dependent variables (maternal age, 
maternal weight and BMI, systolic and diastolic pressure, dipstick, parity, gravidity, number 
of pregnancy losses, gestational age at birth, baby weight, and laboratory variables) were 
numerical data; these were classified on whether they had normally or non-normally 
distributed data. For comparing the effect of the binary independent variable (HIV-status) on 
dependent variables with normally distributed data the Independent samples T-test was used. 
For comparing the effect of the binary independent variable (HIV-status) on dependent 
variables with non-normally distributed data the Mann-Whitney test was used. For comparing 
the effects of the nominal independent variables (pregnancy type and study groups) on 
dependent variables with normally distributed data the one-way analysis of variance 
(ANOVA) test was used. For comparing the effects of the nominal independent variables 
(pregnancy type and study groups) on dependent variables with non-normally distributed data 









3.1. Study groups 
Cell surface glycoproteins of NK cells (CD3, CD16, CD56 and CD69) were assessed in HIV-
positive and HIV-negative pre-eclamptic and normotensive patients attending the antenatal 
and labour ward at the Prince Mshiyeni Memorial Hospital. A total of 160 pregnant Black 
South Africans were studied. Study groups were as follows: 
1) Pre-eclamptic (n=102) 
(a) EOPE (n=73) 
i. HIV-positive (n=35) 
ii. HIV-negative (n=38) 
(b) LOPE (n=29) 
i. HIV-positive (n=11) 
ii. HIV-negative (n=18) 
2) Normotensive (n=58) 
(a) HIV-positive (n=30) 
(b) HIV-negative (n=28) 
 
The EOPE study group accounted for 45.63% of the study population. The EOPE study group 
was distributed between HIV-positive (21.88%) and HIV-negative (23.75%) subgroups. LOPE 
study group accounted for 18.13% of the study population. HIV infection within the LOPE 
group accounted for 6.88% of the study population whilst HIV-negative accounted for 
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11.25%. The normotensive study group was evenly distributed between HIV-positive and 
HIV-negative subgroups and accounted for 36.25% collectively. 
 
3.2. Patient clinical characteristics 
Table 3.1: Mean, standard deviation and skewness values of the study population’s clinical 
characteristics. 
 N Mean SD Skewness Std. Error of 
Skewness 
 Valid Not 
determined 
    
Maternal age 
(years) 
158 2 27 6.93 0.61 0.19 
Maternal weight 
(Kg) 
158 2 74.63 17.75 0.62 0.19 
BMI (Kg/m
2
) 121 39 29.93 6.75 0.60 0.22 
Systolic pressure 
(mmHg) 
159 1 140.32 27.07 -0.15 0.19 
Diastolic pressure 
(mmHg) 
159 1 89.57 17.81 -0.31 0.19 
Dipstick 
(mg/d) 
151 9 1.07 0.88 0.69 0.19 
Parity  159 1 1.06 1.15 1.96 0.19 
Gravidity 159 1 2.33 1.63 2.99 0.19 
No. of pregnancy 
losses 
160 0 0.17 0.60 5.53 0.19 
GA at birth (weeks) 117 43 35.74 4.34 -1.23 0.22 
Birth weight (Kg) 117 43 2.62 0.95 -0.30 0.22 






















23.64±4.42 26.87±6.36 27.58±7.36 27.88±7.14 26.24±7.38 31.64±8.27 p=0.062 
Maternal 
weight (Kg) 
73.96±18.88 68.76±16.58 77.81±18.04 77.76±17.50 71.34±17.90 76.85±16.06 p=0.346 




110.21±11.77 108.23±11.75 158.84±13.47 159.71±16.31 152.29±10.69 160.27±10.85 p<0.001 
Diastolic 
pressure 
(mmHg) 68.86±9.87 68.7±5.91 102.71±8.51 101.8±8.85 98.76±7.24 100.73±7.67 
p<0.001 
Dipstick 
(mg/d) 0.5±0.95 0.15±0.37 1.57±0.69 1.51±0.74 1.25±0.58 1.27±0.47 
p<0.001 
Parity 
0.61±0.69 1.03±0.85 1.08±1.10 1.26±1.54 1±1.06 1.64±1.5 
p=0.233 
Gravidity 1.79±0.83 2.37±1.35 2.32±1.44 2.69±2.29 2.41±1.81 2.45±1.7 p=0.454 
GA at birth 
(weeks) 39.07±1.54 39.20±1.32 33.85±4.27 33.09±4.85 37.85±1.21 37.80±1.69 
p<0.001 
Birth weight 
(Kg) 3.389±0.36 3.321±0.49 2.149±0.83 2.056±0.90 3.029±0.50 3.346±1.04 
p<0.001 
Values are given as Mean ± Standard Deviation (SD)  
 
3.2.1. Maternal age 
Of the study population; 158 participants’ maternal age was recorded. The mean ± SD of the 
maternal age of the 158 study participants was 27 ± 6.93 years. The maternal age ranged 
between 18 to 44 years. The raw data of the maternal age had a skewness value of 0.61 with 
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standard error of 0.19; this indicated that the data was not normally distributed across the 
study population. 
 
The Mann-Whitney test was used to indicate the effect of HIV-statues on maternal age across 
the study population (U= 2562.50, p= 0.055). The analysis showed that there was no 
significant difference in maternal age between the HIV-negative group (mean rank= 72.87) 
and the HIV-positive group (mean rank= 86.83). The Kruskal-Wallis Test was used to show 
the correlation between pregnancy type (normotensive, early pre-eclamptic or late pre-
eclamptic) and maternal age across the study population (n= 158).  Analysis showed that there 
was no significant difference in maternal age between the pregnancy types (p= 0.165). The 
Kruskal-Wallis Test was also used to show the correlation between study groups and maternal 
age across the study population (n= 158).  There was no significant difference in maternal age 
across the study groups (p= 0.062). 
 
3.2.2. Maternal weight 
Of the study population; 158 participants’ maternal weight was recorded. The mean ± SD of 
the maternal weight was 74.63 ± 17.75 Kilograms (Kg). The minimum maternal weight was 
41 kg whilst the maximum weight was 125 kg. The maternal weight raw data of the study 
population had a skewness value of 0.62 with standard error of 0.19; this indicated that the 




The Mann-Whitney test was used to indicate the effect of HIV-statues on maternal weight 
across the study population (U= 3112.00, p= 0.999). The analysis showed that there was no 
significant difference in maternal weight between the HIV-negative group (mean rank= 79.49) 
and the HIV-positive group (mean rank= 79.51). The Kruskal-Wallis Test was used to show 
the correlation between pregnancy type (normotensive, early pre-eclamptic or late pre-
eclamptic) and maternal weight across the study population (n= 158).  Analysis showed that 
there was no significant difference in maternal age between the pregnancy types (p= 0.117). 
The Kruskal-Wallis Test was also used to show the correlation between study groups and 
maternal weight across the study population (n= 158).  There was no significant difference in 
maternal weight across the study groups (p= 0.346). 
 
3.2.3. Body mass index (BMI) 
Of the study population; only 121 participants’ BMI was recorded. The mean ± SD of the BMI 
of the 121 study participants was 29.93 ± 6.75 Kilograms per square meter (Kg/m
2
). BMI 
ranged between 18.2 - 49.7 Kg/m
2
. The raw data of the BMI of the study population had a 
skewness value of 0.60 with standard error of 0.22; this indicated that the data was not 
normally distributed across the study population. 
 
The Mann-Whitney test was used to indicate the effect of HIV-statues on the maternal BMI 
across the study population (U= 1799.50, p= 0.899). The analysis showed that there was no 
significant difference in the maternal BMI between the HIV-negative group (mean rank= 
60.62) and the HIV-positive group (mean rank= 61.43). The Kruskal-Wallis Test was used to 
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show the correlation between pregnancy type (normotensive, early pre-eclamptic or late pre-
eclamptic) and maternal BMI the study population (n= 121).  Analysis showed that there was 
no significant difference in maternal BMI between the pregnancy types (p= 0.298). The 
Kruskal-Wallis Test was also used to show the correlation between study groups and maternal 
BMI across the study population (n= 121).  There was no significant difference in maternal 
BMI across the study groups (p= 0.536). 
 
3.2.4. Systolic pressure 
Of the study population; 159 participants’ systolic pressures were recorded. The mean systolic 
pressure of the 159 study participants was 140.32 mmHg with standard deviation of 27.07 
mmHg. The systolic pressure ranged between 85 - 218 mmHg. The raw data of the systolic 
pressure had a skewness value of -0.148 with standard error of 0.192; this indicated that data 
for systolic pressure across the study population was normally distributed.   
 
An Independent Samples T-test was used to indicate the effect of HIV-statues on systolic 
pressure across the study population [F (159) = 2.604, p= 0.109]. There was no significant 
difference in the systolic pressure of the HIV-negative group (mean ± SD: 141.1 ± 25.45 
mmHg) compared to the HIV-positive group (mean ± SD: 139.47 ± 28.89 mmHg). The one-
way ANOVA was used to show the effect of pregnancy type (normotensive, EOPE or LOPE) 
on systolic pressure [F (159) = 256.402, p< 0.001]. There was a difference in the systolic 




Normotensive study participants had the lowest mean systolic pressure (mean ± SD: 109.19 ± 
11.69 mmHg, Confidence Interval (CI) 95%: 106.1–112.27 mmHg). LOPE study participants 
had a mean systolic pressure of 155.43 ± 11.27 mmHg (CI 95%: 151.06-159.80 mmHg), and 
EOPE study participants had the highest mean systolic pressure (mean ± SD: 159.26 ± 14.80 
mmHg, CI 95%: 155.81– 162.71 mmHg).    
 
A one-way ANOVA and post hoc Tukey B test indicated that systolic pressure was 
significantly different across all study groups (F (159)= 103.042, p< 0.001). The mean systolic 
blood pressure of the HIV-negative normotensive study group (mean ± SD: 110.21 ± 11.77 
mmHg, CI 95%: 105.65-114.78 mmHg) was significantly lower than the HIV-negative EOPE 
group (mean ± SD: 158.84 ± 13.47 mmHg, CI 95%: 154.41-163.27 mmHg) and the HIV-
negative LOPE group (mean ± SD: 152.29 ± 10.687 mmHg, CI 95%: 146.80-157.79 mmHg). 
Alternately, the systolic blood pressure of the HIV-positive normotensive group (mean ± SD: 
108.23 ± 11.746 mmHg, CI 95%: 103.85-112.62 mmHg) was significantly lower than the 
mean systolic pressure of the HIV-positive EOPE group (mean ± SD: 159.71 ± 16.314 mmHg, 
CI 95%: 154.11-165.32 mmHg) and the HIV-positive LOPE group (mean ± SD: 160.27 ± 
10.845 mmHg, CI 95%: 152.99-167.56 mmHg). Mean systolic blood pressure in HIV-
negative EOPE, HIV-positive EOPE, HIV-negative LOPE, HIV-positive LOPE study groups 
were significantly higher than the systolic pressure of both the HIV-positive and HIV-negative 
normotensive study groups (p< 0.001). Additionally the systolic pressure of the HIV-negative 
normotensive study group was significantly higher than the systolic pressure of the 
normotensive HIV-positive group (p< 0.001).   
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3.2.5. Diastolic pressure 
Of the study population; 159 participants’ diastolic blood pressure was recorded. The mean 
diastolic pressure was 89.57 ± 17.81 mmHg. The diastolic blood pressure ranged between 54 -
130 mmHg. The raw data of the diastolic pressure had a skewness value of -0.306 with 
standard error of 0.192; this indicated that data for diastolic pressure across the study 
population was normally distributed. 
 
An Independent Samples T-test was used to indicate the effect of HIV-statues on diastolic 
pressure across the study population [F (159) = 0.496, p= 0.483]. There was no significant 
difference in the diastolic pressure of the HIV-negative group (mean ± SD: 90.48 ± 17.84 
mmHg) compared to the HIV-positive group (mean ± SD: 88.58 ± 17.84 mmHg). The one-
way ANOVA was used to show the effect of pregnancy type (normotensive, EOPE or LOPE) 
on diastolic blood pressure across the study population [F (159) = 295.673, p< 0.001]. A 
significant difference in the mean diastolic blood pressure across the pregnancy types was 
demonstrated (p< 0.001). Normotensive study participants had the lowest mean diastolic 
pressure (mean ± SD: 68.78 ± 7.99 mmHg, CI 95%: 66.67 – 70.88 mmHg). LOPE study 
participants had a mean diastolic pressure of 99.54 ± 7.34 mmHg (CI 95%: 96.69– 102.38 
mmHg). EOPE study participants had the highest mean diastolic pressure (mean ± SD: 102.27 
± 8.63 mmHg, CI 95%: 100.26– 104.29 mmHg).     
 
The one-way ANOVA and post hoc Tukey B test indicated that diastolic pressure was 
significantly different between all study groups (F (159) = 116.575, p< 0.001). The mean 
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diastolic blood pressure of the HIV-negative normotensive study group (mean ± SD: 68.86 ± 
9.87 mmHg, CI 95%: 65.03-72.69 mmHg) was significantly lower than that of the HIV-
negative EOPE (mean ± SD: 102.71 ± 8.51 mmHg, CI 95%: 99.91-105.51mmHg) and HIV-
negative LOPE study group (mean ± SD: 98.76 ± 7.242 mmHg, CI 95%: 95.04-102.49 
mmHg). Alternately, the diastolic pressure of the HIV-positive normotensive study group 
(mean ± SD: 68.70 ± 5.91 mmHg, CI 95%: 66.49-70.91 mmHg) was significantly lower than 
that of the HIV-positive EOPE (mean ± SD: 101.80 ± 8.85 mmHg, CI 95%: 98.76-104.84 
mmHg) and HIV-positive LOPE (mean ± SD: 100.73 mmHg ± 7.669 mmHg, CI 95%: 95.57-
105.88 mmHg) study groups (p< 0.001). Mean diastolic blood pressure in HIV-negative and 
HIV-positive EOPE and LOPE study groups were significantly higher than the diastolic 
pressure of both the HIV-positive and HIV-negative normotensive study groups (p< 0.001). 
 
3.2.6. Urine protein dipstick measurements 
Of the study population; 151 participants’ proteinuria (1+ being between 30-100mg/d) was 
recorded. The mean proteinuria of the 151 study participants was 1.07 ± 0.88, ranging from 0 
to 4. The raw data of the proteinuria of the study population had a skewness value of 0.689 
with standard error of 0.197; this indicated that the data was not normally distributed across 
the study population. 
 
The Mann-Whitney test was used to indicate the effect of HIV-statues on the proteinuria 
across the study population (U= 2543.00, p= 0.228). The analysis showed that there was no 
significant difference in the proteinuria value between the HIV-negative group (mean rank= 
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79.81) and the HIV-positive group (mean rank= 71.82). The Kruskal-Wallis Test was used to 
show the correlate proteinuria on between pregnancy type (normotensive, EOPE or LOPE) 
and the urine protein dipstick measure within the study population (n= 151).  Analysis showed 
that there was a difference in the mean proteinuria values between the pregnancy types (p< 
0.001). Normotensive group had the lowest dipstick values (mean rank= 36.78). The EOPE 
group (mean rank= 99.71) had higher proteinuria values than the LOPE group (mean rank= 
88.31).  
 
The Kruskal-Wallis Test was also used to show the correlation between study groups and the 
proteinuria within the study population (n= 151).  Analysis showed that there was a difference 
in the proteinuria between the study groups (p< 0.001). The normotensive HIV- positive study 
group had the lowest urine proteinuria (mean rank= 29.12) compared to all the study groups. 
The early pre-eclamptic HIV-negative study group (mean rank= 101.53) had highest dipstick 
values compared to all the study groups (p< 0.001). Additionally, proteinuria for the HIV- 




Of the study population; the parity of 159 participants’ was recorded. Mean parity of the 159 
study participants was 1.06 ± 1.154. The parity range of the study population was 0 to 8. Raw 
data of the study population’s parity had a skewness value of 1.964 with standard error of 




The Kruskal-Wallis Test was used to show the correlation between pregnancy type 
(normotensive, EOPE or LOPE) and parity of the study population (n= 159).  Analysis showed 
that there was no significant difference in parity between the pregnancy types (p= 0.342). The 
Kruskal-Wallis Test was also used to show the correlation between study groups and parity 
across the study population (n= 159).  Analysis showed that there was no significant 
difference in parity between the study groups (p= 0.233). 
 
3.2.8. Gravidity 
Of the study population; the gravidity of 159 participants’ was recorded. Mean gravidity of the 
159 study participants was 2.33 ± 1.629, ranging from 0 to 14. Raw data of the study 
population’s gravidity had a skewness value of 2.997 with standard error of 0.192; this 
indicated that the data was not normally distributed. 
 
The Kruskal-Wallis Test was used to show the correlation between pregnancy type 
(normotensive, EOPE or LOPE) and gravidity of the study participants’ (n= 159). Analysis 
showed that there was no significant difference in gravidity between the pregnancy types (p= 
0.508). The Kruskal-Wallis Test was also used to show the correlation between study groups 
and gravidity across the study population (n= 159).  Analysis showed that there was no 




3.2.9. Number of pregnancy losses 
The number of pregnancy losses of all the participants of the study was recorded. The mean 
number of pregnancy losses was 0.17 ± 0.60, ranging from 0 to 8. Raw data of the number of 
pregnancy losses had a skewness value of 5.53 with standard error of 0.192; this indicated that 
the data was not normally distributed. 
 
The Mann-Whitney test was used to indicate the effect of HIV-statues on the number of 
pregnancy losses across the study population (U= 3126.50, p= 0.690). The analysis showed 
that there was no significant difference in the number of pregnancy losses between the HIV-
negative group (mean rank= 81.28) and the HIV-positive group (mean rank= 79.64). The 
Kruskal-Wallis Test was used to show the correlation between pregnancy type (normotensive, 
EOPE or LOPE) and number of pregnancy losses of the study participants’ (n= 160). Analysis 
showed that there was no significant difference in the number of pregnancy losses between the 
pregnancy types (p= 0.277). The Kruskal-Wallis Test was also used to show the correlation 
between study groups and and number of pregnancy losses of the study participants’ (n= 160). 
There was no significant difference in the number of pregnancy losses between the study 
groups (p= 0.643). 
 
3.2.10. GA at birth 
The GA of 117 study participants was recorded. The mean GA was 35.74 ± 4.344 weeks. The 
minimum GA was 22 weeks whilst the maximum was 41 weeks. The raw data of the GA of 
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the infants had a skewness value of   -1.233 with standard error of 0.224; this indicated that the 
data was not normally distributed. 
 
The Mann-Whitney test was used to indicate the effect of HIV-statues on GA of infants of the 
study population (U= 1705.00, p= 0.978). The analysis showed that there was no significant 
difference in the GA of the infants between the HIV-negative group (mean rank= 59.08) and 
the HIV-positive group (mean rank= 58.91). The Kruskal-Wallis Test was used to show the 
correlation between pregnancy type (normotensive, EOPE or LOPE) and the GA at birth of 
infants of the study population (n= 117).  Analysis showed that there was a difference in the 
GA of the infants between the pregnancy types (p< 0.001). Early pre-eclamptic study 
participants (mean rank= 39.25) had infants with the lowest GA at birth compared to the late 
pre-eclamptic (mean rank= 74.28) and the normotensive (mean rank= 91.16) study 
participants. Normotensive study participants had infants with the highest GA at birth. 
 
The Kruskal-Wallis Test was also used to show the correlation between study groups and the 
GA at birth of infants of the study population (n= 117).  Analysis showed that there was a 
difference in the GA of the infants between the study groups (p< 0.001). The early pre-
eclamptic HIV-positive study group (mean rank= 38.13) had infants with the lowest GA at 
birth and the normotensive HIV-positive study groups (mean rank= 92.80) had infants with the 




3.2.11. Birth weight 
The birth weight of 117 study participants was recorded. The mean birth weight was 2.62 Kg 
± 0.95 Kg. The minimum birth weight was 0.43 Kg and the maximum was 5.8 Kg. The raw 
data of the birth weight had a skewness value of -0.295 with standard error of 0.224; this 
indicated that data for birth weight was normally distributed. 
 
An Independent Samples T-test was used to indicate the effect of HIV-statues on birth weight 
across the study population [F (116) = 0.741, p = 0.391]. This analysis showed that there was 
no significant difference in the birth weight of the HIV-negative compared to the HIV-positive 
group (2.63 ± 0.87 Kg versus 2.63 ± 1.05 Kg; p= 0.391). The one-way ANOVA was used to 
show the effect of pregnancy type (normotensive, EOPE or LOPE) on birth weight across the 
study population [F (116) = 34.586, p< 0.001].  This analysis demonstrated a significant 
difference in the mean birth weight based on pregnancy type (p< 0.001). Babies of the 
normotensive group had the highest birth weight (mean ± SD: 3.35 ± 0.43 Kg, CI 95%: 3.19– 
3.52 Kg) compared to the babies of the LOPE group (mean ± SD: 3.17 ± 0.78 Kg; CI 95%: 
2.83– 3.5 Kg) and EOPE group (mean ± SD: 2.1 ± 0.86 Kg, CI 95%: 1.87– 2.32 Kg). 
 
The one-way ANOVA and post hoc Tukey B test indicated that the infant birth weight 
differed significantly across all study groups (F (116) = 13.878, p< 0.001). The birth weight of 
the HIV-negative EOPE study group (mean ± SD: 2.15 ± 0.83 Kg, CI 95%: 1.86-2.44 Kg) was 
significantly lower than the birth weight of the HIV-negative normotensive (mean ± SD: 3.39 
± 0.36 Kg, CI 95%: 3.18-3.60 Kg) and the HIV-negative LOPE (mean ± SD: 3.03 ± 0.50 Kg, 
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CI 95%: 2.73-3.33 Kg) study groups. Alternately, the birth weight within the HIV-positive 
EOPE study group (mean ± SD: 2.06 ± 0.90 Kg, CI 95%: 1.73-2.38 Kg) was significantly 
lower than that within the HIV-positive normotensive (mean ± SD: 3.32 ± 0.49 Kg, CI 95%: 
3.05-3.59 Kg) and HIV-positive LOPE (mean ± SD: 3.35 ± 1.04 Kg, CI 95%: 2.61-4.09 Kg) 
study groups (p< 0.001). Mean birth weight in HIV-negative and HIV-positive normotensive 
and LOPE study groups were significantly higher than the birth weight of both the HIV-
negative and HIV-positive EOPE study groups (p< 0.001).  
 
3.3. Analysis of NK cells 
Table 3.3: Mean, standard deviation and skewness values of the number of WBC cells in the 
study population. 
 N Mean SD Skewness Std. Error 
of Skewness 
 Valid Not 
determined 
    
Lymphocyte cells 
158 2 85556.32 67834.55 2.76 0.19 
Single cells 




157 3 40536.85 55069.81 4.58 0.19 
uNK cells 




75 85 9.47 14.32 1.94 0.28 
pNK cells 




158 2 62.69 129.73 4.99 0.19 
N= Study Population 
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+ve  pNK 
cells 
(p= 0.003) 
40.46±52.32 17.90±26.28 60.38±90.57 106.97±171.82 35.22±48.37 162.30±325.55 
Values are given as mean±SD 
 
3.3.1. Total number of lymphocytes 
The total number of lymphocytes of 158 study participants was recorded. Mean lymphocyte 
count was 85556.32 ± 67834.55 cells. The minimum lymphocyte count in the study 
participants was 7497 cells and the maximum was 509601. The raw data of the lymphocytes 




The Mann-Whitney test revealed a significant effect of HIV-statues on the lymphocyte count 
across the study population (U= 2230, p= 0.002). Additionally, the HIV-positive group (mean 
rank= 91.27) had significantly higher level of lymphocytes than the HIV-negative group 
(mean rank= 68.87; p= 0.002).  
 
The Kruskal-Wallis Test showed a significant difference in the level of lymphocyte count 
based on pregnancy types (normotensive, EOPE or LOPE; p< 0.001). The lowest mean 
lymphocyte count was observed in the normotensive group (mean rank: 55.88) compared to 
the EOPE and LOPE group (mean rank: 91.74 and 96.96 respectively). Additionally, there 
was a higher lymphocyte count in the LOPE group compared to the EOPE group (p< 0.001).  
 
 The Kruskal-Wallis Test analysis (n= 158) demonstrated a significant difference in the level 
of lymphocyte count amongst the study groups. The HIV-positive LOPE study group had the 
highest levels of lymphocytes and the HIV-negative normotensive study group had the lowest 
levels (p< 0.001). 
 
3.3.2. Lymphocyte single cell levels 
The lymphocyte single cell count of 158 study participants was recorded. Mean single cell 
count was 83789.97 ± 67280.21 cells;   range: 6785 - 502661 cells. The raw data of single 
cells had a skewness value of 2.74 with standard error of 0.19; this indicated that the data was 
not normally distributed. 
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The Mann-Whitney test showed a significant effect of HIV-statues on the level of lymphocyte 
single cells across the study population (U= 2214, p= 0.002). The HIV-positive group (mean 
rank= 91.48) had a significantly higher level of lymphocyte single cells compared to the HIV-
negative group (mean rank= 68.67). The Kruskal-Wallis Test showed a significant difference 
in the level of lymphocyte single cells across the pregnancy types (n= 158; normotensive, 
EOPE or LOPE; p< 0.001). The normotensive group (mean rank: 55.47) had the lowest mean 
lymphatic cell count. Additionally, the LOPE group had a significantly higher lymphatic cell 
count compared to the EOPE group (mean rank: 97.07 versus 92.03, p< 0.001). 
 
The Kruskal-Wallis Test showed a significant difference in the level of lymphocyte single 
cells amongst the study groups. The HIV-positive EOPE study group had the highest levels 
(mean rank: 100.80) and HIV-negative normotensive had the lowest levels (mean rank: 31.50) 
of single cells (p< 0.001). 
 
3.3.3. CD3 negative lymphocyte levels 
The CD3 negative cell count of 157 study participants was recorded. Mean CD3 negative cell 
count was 40536.85 ± 55069.81 cells (range: 1977 - 478246 cells). The raw data of the CD3 
negative cells had a skewness value of 4.58 with standard error of 0.19; this indicated that data 




The Mann-Whitney test demonstrated a significant effect of HIV-statues on the level of CD3 
negative cells across the study population (U= 2350, p= 0.011). The HIV-positive group 
(mean rank= 88.74) had significantly higher levels of CD3 negative cells than the HIV-
negative group (mean rank= 70.31). The Kruskal-Wallis Test showed that there was a 
significant difference in the level of CD3 negative cells based on pregnancy type (n= 157; 
normotensive, EOPE or LOPE; p< 0.001). Normotensive group (mean rank: 50) had the 
lowest mean CD3 negative cell count compared to the EOPE and LOPE groups (mean rank: 
95.99 and 94.36 respectively). 
 
The Kruskal-Wallis Test demonstrated a significant difference in the level of CD3 negative 
cells amongst the study groups (n= 157; p< 0.001). Additionally, the HIV-positive EOPE 
study group had the highest levels of CD3 negative cells compared to all the other study 
groups (p< 0.001). 
 
3.3.4. uNK Cell Levels 
The uNK cell count of 75 study participants was recorded. Mean uNK cell count was    251.19 
± 439.05 cells (range: 0 - 2177 cells). The raw data of the uNK cells had a skewness value of 
2.87 with standard error of 0.28; this indicated that the data was not normally distributed. 
 
The Mann-Whitney test showed no effect of HIV-statues on the level of uNK cell count across 
the study population (U= 525, p= 0.063). The Kruskal-Wallis Test demonstrated no significant 
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difference in the levels of uNK cells based on the pregnancy types (n= 75; normotensive 
versus EOPE versus LOPE; p= 0.184). The Kruskal-Wallis Test was also used to show the 
correlation between study groups and uNK cells across the study population (n= 75). Analysis 
showed no significant difference in the levels of uNK cells between the study groups (p= 
0.163). 
 
3.3.5. CD69 positive-uNK Cell Levels 
The CD69 positive-uNK cell count of 75 study participants was recorded. The mean CD69 
positive-uNK cell count was 9.47 ± 14.32 cells (range:  0 - 54 cells). The raw data of the CD69 
positive-uNK cells had a skewness value of 1.94 with standard error of 0.28; this indicated 
that the data was not normally distributed. 
 
The Mann-Whitney test demonstrated no significant effect on levels of CD69 positive-uNK 
cells based on the HIV status (U= 662, p= 0.682). Similarly, there was no significant 
difference in the level of CD69 positive-uNK cells based on the pregnancy type (p= 0.06). 
Additionally the Kruskal-Wallis Test demonstrated no significant difference in the level of 
CD69 positive-uNK cells amongst the study groups (p= 0.195). 
 
3.3.6. pNK Cell Levels 
The pNK cell count of 158 study participants was recorded. The mean pNK cell count was    
1119.27 ± 1889.99 cells (range: 0 - 14101 cells). The raw data of the pNK cells had a 
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skewness value of 3.52 with standard error of 0.19; this indicated that the data was not 
normally distributed. 
 
The Mann-Whitney test showed a significant effect of HIV-statues on level of pNK cells 
across the study population (U= 2548.50, p= 0.05). The HIV-negative group (mean rank= 
86.30) had significantly higher levels of pNK cells than the HIV-positive group (mean rank= 
71.98). The Kruskal-Wallis Test no significant difference in the levels of pNK cells between 
the pregnancy types (n= 158; normotensive versus EOPE versus LOPE; p= 0.451). 
Additionally there was no significant difference in the levels of pNK cells between the study 
groups (n= 158; p= 0.061; Kruskal-Wallis Test). 
 
3.3.7. CD69 positive-pNK Cell Levels 
The CD69 positive-pNK cell count of 158 study participants was recorded. The mean cell 
count was recorded to be 62.69 ± 129.73 cells (range: 0 - 1075 cells). The raw data had a 
skewness value of 4.99 with standard error of 0.19; this indicated that the data was not 
normally distributed. 
 
The Mann-Whitney test showed no significant difference on the level of CD69 positive-pNK 
cells based on HIV status (U= 3033.50, p= 0.783). The Kruskal-Wallis Test showed a 
significant difference in level of CD69 positive-pNK cells based on the pregnancy types (n= 
158; normotensive versus EOPE versus LOPE; p= 0.009). The normotensive group (mean 
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rank: 64.85) had the lowest mean CD69 positive-pNK cell count compared to the EOPE and 
LOPE groups (mean rank: 88.77 and 86.00 respectively). Moreover, results showed that the 
HIV-positive LOPE study group had the highest levels in CD69 positive-pNK cells compared 







4.1. Maternal mortality 
Maternal deaths in the world have significantly decreased over the past years, yet still about 
800 women die every day due to pregnancy and childbirth related causes (WHO 2010). 
According to a report done by the World Health Organization (WHO) in 2010, almost all 
maternal deaths occur in developing countries due to low-resource settings and a lack of 
skilled care during and after childbirth.  In a report done in South Africa to look at maternal 
deaths between 2011-2013, 50% of the maternal deaths were due to hypertension and non-
pregnancy related infection mainly HIV, Tuberculosis (TB)  and pneumonia (Pattinson 2014). 
Therefore studies focusing on decreasing maternal deaths in South Africa and the world still 
remain an important sector in the research domain. 
 
Immunology studies focusing on NK cells are imperative in pregnancy and HIV-associated 
disorders. These cells are one of the early recruited and activated cells in the first phase of the 
immune system’s fight against pathogens, making them early markers for a disturbed 
environment (Vacca, Moretta et al. 2011, Vivier, Raulet et al. 2011). In the maternal body, 
both uNK and pNK cells play a vital role in indicating whether there is a disruption in the 
normal progression of pregnancy. Analysis of the function and activation status of NK cells 
during pregnancy is very important, especially as the role of these cells is not fully recognized 
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post implantation in both normal and pathological pregnancies (Mosimann, Wagner et al. 
2013).  
 
4.2. Maternal characteristics  
The aetiology of PE remains elusive, yet various maternal factors have been associated with 
increasing the risk of developing this disorder (Rebelo, Schlüssel et al. 2013). Numerous 
studies have investigated some of these factors and yielded results that contribute to the better 
understanding and management of PE. In this study various maternal characteristics presented 
at antenatal admission, that may indicate a higher probability of developing PE, were 
investigated.  
 
4.2.1. Maternal age on PE development 
The results of this study yielded no significant difference when looking at maternal age versus 
pregnancy type and HIV-associated pregnancy. This was contradictory to other studies that 
have been performed on larger study populations. In this study population the maternal age 
ranged from 18 to 44 years, which is a range that is not considered to greatly affect PE 
development. 
 
A study by Ananth et al (2013) indicated that women of younger (<18 years) and mature (>40 
years) age had a greater risk of developing PE. Additionally, Duckitt and Harrington (2005) 
reported that the risk of developing PE was almost double in women aged ≥ 40 years, and that 
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women also experienced a 30% risk increase for every additional year over the age of 34 
years. In contrary, de Vienne et al (2009) reported that women of younger (<18 years) child 
barring age were associated with a lower risk of developing PE and having delivery 
complications. The myocardial function and connective tissue elasticity in younger women is 
in better condition, making the maternal body more suited for pregnancy development (de 
Vienne, Creveuil et al. 2009).  Additionally, pregnancy complications and illness like 
gestational diabetes and PE are higher in mature women over the age of 40 years, predisposing 
these women to an increased risk of developing PE (Jacobsson, Ladfors et al. 2004).  
 
Unsuccessful pregnancies, foetal mortalities and premature births are therefore higher in 
women of mature age (≥ 40 years) compared to younger women of child barring age (20-29 
years) (Cleary-Goldman, Malone et al. 2005). In most studies the negative effects of age on 
pregnancy is seen to be significantly reduced in cases where good prenatal and postnatal care 
was given to both the mother and child (Jacobsson, Ladfors et al. 2004). 
 
4.2.2. Weight and BMI on PE development 
The results of this study yielded no significant difference when looking at maternal weight and 
BMI versus pregnancy type and HIV-associated pregnancy. This was inconsistent with other 
studies conducted in other countries associating weight with pregnancy complications. It is 
plausible to suggest that we didn’t get a significant difference in the study because South 
African women are normally overweight even pre-pregnancy (Katz, O’Connell et al. 2005). 
Additionally, in 2005, Obesity Task Force reported that South Africa is among the top 3 
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countries with highest incidences of obesity globally, especially among women of 
reproductive age.  
 
 Many studies have associated maternal weight and the biochemical factors of being over 
weight with pregnancy complications and birth outcomes. A study by Rebelo et al (2013) 
showed that in pre-eclamptic women the inflammatory cytokines and maternal weight was 
higher compared to normotensive pregnant women. Increase in weight and BMI ultimately 
increases inflammatory cytokines like C-reactive protein, in this way increasing the risk of 
developing PE (Rebelo, Schlüssel et al. 2013). This evidence further implicates the immune 
system in the pathogenesis of PE. Haugen et al (2014) not only implicated maternal weight 
pre-pregnancy to adverse pregnancy and birth outcomes, but also associated maternal 
gestational weight gain (GWG) to the PE epidemic. Haugen et al (2014) also concluded that 
excessive weight gain during pregnancy negatively affect pregnancy and delivery outcomes in 
all women irrespective of their parity and gravidity states. Excessive GWG is also seen to 
increase the risk of maternal post-partum weight retention (PPWR) in women (Haugen, 
Brantsæter et al. 2014). Weight retention post-pregnancy may also have clinical complications 
associated with obesity and weight gain, causing maternal morbidity. 
 
In contrary, a study by Heude et al (2012) identified that women who were over weight or 
obese gained less weight during their pregnancy. In this way over weight and/or obese women 
were at lower risk of developing PPWR. Weight gain in over weight and/or obese women has 
been speculated to be physiologically unnecessary due to the fact that fat stores to facilitate 
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pregnancy and lactation are already available, causing limited weight gain (Heude, 
Thiébaugeorges et al. 2012). 
    
4.2.3. Blood pressure as one of the diagnostic tools for PE 
Significant difference was shown in blood pressure between the pregnancy types. From the 
results of this study it was observed that both systolic and diastolic pressures were higher in 
the EOPE and LOPE women compared to normotensive women. Minimum raise in blood 
pressure was seen in normal pregnancies due to the natural increase of demand of oxygen and 
nutrients to supply both mother and child.  
 
EOPE women had the highest blood pressure compared to both normotensive and LOPE 
women. EOPE develops early in pregnancy (<34 weeks of gestation) causing severe 
restrictions to the development and progression of the pregnancy, while LOPE develops later 
in the pregnancy (≥34 weeks of gestation) causing limited effects on both the mother and the 
child (Raymond and Peterson 2011, Li, Chen et al. 2014). EOPE is highly associated with 
abnormal placentation leading to constriction of maternal blood vessels that perfuse the 
placenta and supply the growing foetus. The early restriction of blood vessel dilation in EOPE 
is responsible for the increased in blood pressure that is seen in this type of PE. 
 
Pregnancy-related hypertension may also affect the mother post-pregnancy due to the 
mobilization of fluid accumulated outside the vascular vessels during pregnancy into the 
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vascular vessels (Moodley 2013). The increase of fluid within the vascular vessels will raise 
the pressure, causing high blood pressure in these women. Continued hypertension post-
partum may also cause pulmonary oedema, which could be detrimental for vital organs 
including the lungs, liver and the heart (Moodley 2013). 
 
4.2.4. Parity and gravidity on PE development 
In this study, there was no significant difference observed in both parity and gravidity based 
on pregnancy type and HIV-associated pregnancy. PE occurs most frequently in young 
primiparous and adult multiparous women (Jasovic-Siveska and Jasovic 2015). Primiparity 
was not an automatic inclusion criterion in this study. Only women 18 years or older were 
included, meaning primiparous women who were ≤18 years old and were admitted into the 
antenatal ward were not sampled.  Women aged above 40 years have twice higher the risk of 
developing PE compared to younger women, irrespective whether they are primiparous or 
multiparous (Jasovic-Siveska and Jasovic 2015). According to Duckitt and Harrington (2005) 
being nulliparous almost triples the risk of developing PE. While the lower overall risk of PE 
among parous women is not explained by fewer pregnancies among women who experienced 






4.3. Foetal characteristics 
 
4.3.1. HIV and PE on Birth weight 
In this study, there was no significant difference in the birth weight of the HIV-negative 
compared to the HIV-positive group (p= 0.391). Maternal nutritional status before and during 
pregnancy is a significant predictor of poor pregnancy outcome; however, its association in the 
presence of HIV infection remains contradictory (Dreyfuss, Msamanga et al. 2001). Low birth 
weight is significantly associated with maternal HIV status, GA, antenatal care, maternal age 
less than 20 years and > 35 years (Mitgitti, Seanchaisuriya et al. 2008). 
 
The results of this study noted significantly higher birth weight babies in the normotensive 
compared to those from the LOPE and EOPE group (p< 0.001). PE/eclampsia is a significant 
risk factor for perinatal death, preterm birth and low birth weight (Ota, Ganchimeg et al. 
2014). PE is a disorder subsequently caused by failure of the utero-placental blood vessels to 
stretch into larger, more efficient blood vessels. This decrease in the utero-placental blood 
flow results in a hypoxic placenta which may alternately lead to a low birth weight, this is due 
to the lack of oxygen reaching the growing foetus (Powe, Levine et al. 2011). Various studies 
have revealed that not all pre-eclamptic women deliver small babies. Opposing the classical 
viewpoint is the recent work by Xiong et al (2001), who concluded that babies born to 
mothers with PE at term have fetal growth similar to that of babies born to normotensive 
mothers. The birth weight is also determined by other maternal factors aside from PE. One of 
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these is the excessive maternal gestational weight gain which according to Haugen et al (2014) 
may lead to an increased foetal birth weight. 
 
We observed the lowest birth weight in the EOPE group compared to the LOPE and 
normotensive groups.  This finding is supported by the fact that EOPE is characterized by 
defective cytotrophoblast placentation, defective spiral artery conversion with resultant poor 
blood flow (Naicker, Khedun et al. 2003). Our results also reflect that PE is an etiologically 
heterogeneous disorder as our EOPE birth weight differed from the LOPE group. Birth weight 
may also be affected by multiple pregnancies, maternal obesity and under weight, inter-current 
chronic medical conditions in pregnancy, anaemia, cigarette smoking, alcohol and other 
substance abuse (England, Levine et al. 2002, Xiong, Buekens et al. 2011). Confounding 
conditions such as maternal obesity and under weight, anaemia, cigarette smoking, alcohol 
and other substance abuse were not exclusion criteria in this study. 
 
4.3.2. HIV and PE on GA 
In this study, there was no significant difference in GA between the HIV-negative group and 
the HIV-positive group (p= 0.978). Significant difference was observed in the GA of the 
infants between the pregnancy types (p< 0.001). As expected, GA was lowest in the EOPE 




Our findings support the hypothesis of placental hypo-perfusion caused by shallow invasion of 
cytotrophoblast in early pregnancy leading to foetal growth restriction in PE (Naicker, Khedun 
et al. 2003). EOPE (before 34weeks) is frequently linked with abnormal spiral arteries, foetal 
growth restriction, and adverse maternal and neonatal outcomes (Ness and Sibai 2006, 
Huppertz 2008). In contrast, LOPE (after 34 weeks) is predominantly correlated with normal 
or slightly elevated uterine resistance index, a low rate of foetal involvement, and better 
perinatal outcomes (Sibai, Dekker et al. 2005). 
 
4.4. Lymphocytes in HIV-associated PE 
The immune system is composed of various cells that act to protect the body against a variety 
of foreign pathogens. Lymphocytes are one of the five types of cells that form part of the 
immune system. T-cells, B-cells and NK cells are all subtypes of lymphocytes that have 
different functions in the fight against foreign pathogens. In this study lymphocytes were 
quantified in an aim to evaluate the levels of these cells in study participants of different HIV 
status, pregnancy type and study groups. 
 
In this study, a significant effect was observed in the lymphocyte count based on the HIV-
status (p= 0.002). Results revealed that there were significantly higher levels of lymphocytes 
in HIV-positive participants compared to HIV-negative participants. Increase in the levels of 
lymphocytes indicates that there is a disease or foreign pathogen present, in this case HIV and 
the paternal antigens. Levels of lymphocytes are increased in the early stages of HIV infection 
and thereafter decrease as the virus over-powers the attempt of the immune system to eradicate 
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it (Lavu, Kutson et al. 2004). The high levels of lymphocytes in could be present in an attempt 
to combat the HIV in the body.  Lavu et al (2004) found that the lower the total lymphocyte 
count, the more clinically advanced was the HIV disease state. Increased levels of CD4-
expressing lymphocytes may also be due to the intake of Antiretroviral (ARV) drugs. In this 
study, all the HIV-positive women were given the ARV drugs to strengthen their immune 
system for the survival of both the mother and the child, and also to decrease the viral load to 
prevent mother-to-child transmission. WHO has submitted that, absolute lymphocyte count 
(ALC) of ≤1200/μL can constitute CD4 cell count of ≤200/μL in resource-constrained 
countries throughout the world (Kakar, Beri et al. 2011). Indicating that lowered lymphocyte 
count is less able to mount an inflammation response and in turn eliminate foreign pathogens.  
 
The study by Boyajian et al (2012) found that there was no difference in the prevalence of PE 
between women on highly active anti-retroviral therapy (HAART) and HIV-negative women. 
While further studies has revealed that HIV-positive pre-eclamptic women who are on 
HAART develop severe cases of this disorder (Wimalasundera, Larbalestier et al. 2002). This 
may be associated to the fact that HAART drugs predispose women to symptoms similar to 
those of severe PE (HELLP and thrombocytopenia), making diagnosis difficult (Boyajian, 
Shah et al. 2012).   
 
Results of this study also revealed lower levels of lymphocytes in normotensive participants; 
LOPE participants had the highest levels of lymphocytes (p< 0.001). PE has been intensively 
identified as an immune triggered disorder. Increase in lymphocytes indicates an activated 
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immune system, which could alternately lead to the development of PE. Lower levels of 
lymphocytes are therefore predicted in normotensive pregnant women due to the absence of 
PE. The levels of T-cell lymphocytes are elevated in normal pregnancies compared to non-
pregnant women due to the role these lymphocytes play in the success of pregnancy 
(Aluvihare, Kallikourdis et al. 2004). Lymphocytes play a vital role in creating a more 
accepting environment in the maternal body, making the presence of these cells important 
(Darmochwal‐Kolarz, Saito et al. 2007).       
 
Additionally, the highest levels of lymphocytes were seen in the HIV-positive LOPE study 
group; HIV-negative normotensive had the lowest levels of lymphocytes (p< 0.001). Results 
of this study contradicted results from a study done by Hall et al (2013) which concluded that 
due to the weak immune system existing in HIV-positive women, the prevalence of PE would 
be lower compared to the general population. Various studies have also stated that presence of 
HIV in pregnant women prevents other aspects involved in the development of PE (Boyajian, 
Shah et al. 2012).  
 
4.4.1. NK cells in HIV-associated PE 
NK cells have been extensively associated with the succession of pregnancy. These cells are 
said to play an important role in preparing a more suitable environment for the growing foetus 
within the maternal body. In this study the NK cells were evaluated through their cell surface 
glycoproteins to validate their role in pathological pregnancies, more specifically PE. Levels 
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of NK cells were evaluated to establish their relation in HIV status, pregnancy type and study 
group.  
 
In this study the NK cells were meticulously differentiated from other lymphocytes within the 
lymphocyte pool as CD3 negative. Levels of CD3 negative lymphocytes were counted and our 
results yielded significant difference in the amount of these cells between the HIV-positive 
and HIV-negative groups (p= 0.011). Our results showed a higher amount of CD3 negative 
cells in the HIV-positive group compared to the HIV-negative.  
 
Normally NK cells constitute approximately 15% of the total peripheral lymphocyte count, 
they are a first line of defence against viral infection and tumour development (Fauci, Mavilio 
et al. 2005). It is therefore anticipated that these cells would be increased in the presence of a 
virus, in this case HIV. Although NK cells are increased in presence of HIV to mount an 
inflammatory response against the virus, various studies have determined that HIV is able to 
compromise the functionality and mechanism of action of these cells (Brunetta, Hudspeth et 
al. 2010). 
 
With regard to the pregnancy type, this study found that there were higher amounts of CD3 
negative NK cells in the pre-eclamptic group (p< 0.001). Additionally, results showed high 
amounts of NK cells in the EOPE compared to the LOPE. In EOPE, the rejection of the 
growing foetus triggers the immune system and the production of increased levels of immune 
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cells (Huppertz 2008). These high amounts of immune cells and the exaggerated inflammatory 
response contributes to the inadequate and incomplete trophoblast invasion of maternal spiral 
arteries and abnormal blood flow of the umbilical arteries (Raymond and Peterson 2011). 
 
This study also established high levels of the CD3 negative NK cells in HIV-positive EOPE 
study group (p< 0.001). EOPE develops early in pregnancy and is associated with and 
increased inflammatory response (Brunetta, Hudspeth et al. 2010). The increased CD3 
negative cell count is an indication of amplified production of inflammatory cells. 
 
4.4.2. Effects of different NK cell sub-groups on HIV-associated PE 
NK cells may be divided into different sub-groups based on the location within the body, the 
surface glycoproteins they express, and their cytotoxicity (Brunetta, Hudspeth et al. 2010). In 
this study the amount of uNK and pNK cells were determined within the CD3 negative NK 
cell population based on the amount of glycoproteins on their surface. The uNK cells were 
defined as CD16 positive and CD56
Bright
, while pNK cells were predominately defined as CD16 
positive and CD56
Dim
. Levels of both NK cell subsets were evaluated based on the HIV status, 
pregnancy type and the study groups. 
 
No significant difference was seen in the peripheral blood with regard to the uNK cell 
population. This was due to that peripheral blood, used in this study, possesses low amounts of 
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uNK cells. uNK cells migrate into the uterus during pregnancy were they are needed and more 
suitable to perform their function (Mosimann, Wagner et al. 2013, Vacca, Mingari et al. 2013).  
 
This study showed significant difference in the amount of pNK cells between the HIV groups 
irrespective of pregnancy type (p=0.005). A higher amount of pNK cells were observed in the 
HIV-negative group compared to the HIV-positive group irrespective of pregnancy type. pNK 
cells are more cytotoxic and possess more CD56 and CD16 glycoproteins which are involved in 
Antibody Dependent Cell Cytotoxicity (ADCC) (Brunetta, Hudspeth et al. 2010, Vacca, 
Moretta et al. 2011).  NK cells in HIV-positive individuals are less cytotoxic, they possess 
dysfunctional surface glycoproteins; this is a defence mechanism of the virus to override the 
immune response (Brunetta, Hudspeth et al. 2010). Less pNK cells were therefore observed in 
the HIV-positive group due to the lack of characteristic surface glycoproteins.  NK cells in 
HIV-positive individuals are also functionally disabled, meaning the NK cells will not be able 
to perform their function during pregnancy- leading to a the development of PE (Brunetta, 
Hudspeth et al. 2010).  
 
There were no significant differences observed between the pregnancy types and study groups 
with regard to both NK cell subsets. Other studies have implicated more cytotoxic pNK cells 
with the EOPE study group. This is as EOPE is associated with higher organ and placental 
dysfunctions (Huppertz 2008, Raymond and Peterson 2011). 
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4.4.3. Effects of CD69-expressing NK cells on HIV-associated PE 
CD69 is one of the early expressed receptors on NK cells in inflammatory sites (Mosimann, 
Wagner et al. 2013). Expression of this glycoprotein means cells have been activated by 
inflammatory cytokines (Sancho, Gómez et al. 2003). The aim of this study was to quantify 
CD69-expressing NK cells in women of different HIV status, pregnancy type (normotensive 
versus EOPE versus LOPE) and HIV-associated pregnancy. This was done to get a clear 
understanding of the role profile of this surface glycoprotein, and also to see if it may be used 
as an early diagnostic biomarker in pre-eclamptic women.  
 
This study revealed no significant difference in the levels of CD69-expressing NK cells in both 
the NK cell subgroups. This could be related to that CD69 is an early expressed receptor, that 
has shown to be present in high levels in acute infections (Hosono, de Boer et al. 2003). CD69 
levels are said to be rapidly decreased when the antigen stimulus is not present (Lund, Boysen 
et al. 2012), referring to that CD69-expression on NK cells may be decreased as the HIV is 
able to override mechanisms of the immune system to eliminate it. In this study the period 
when the women were first diagnosed with HIV was not documented, meaning we were 
unable to determine whether these women were in the acute or chronic stages of infection. 
  
With regard to pregnancy type, levels of CD69-expressing pNK cells were shown to be 
significantly different (p= 0.009). Results of this study showed higher levels of CD69 positive-
pNK cells in women diagnosed with EOPE. A study by Thum et al (2004) also showed that 
levels of CD69 positive-pNK cells were higher in women who had failed pregnancy. EOPE is 
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regarded as one of the severe type of PE associated with detrimental effects on both mother 
and child (Huppertz 2008). A study by Roussev et al (2013) found that factors released by the 
placenta to render NK cells less cytotoxic decreased the levels of CD69 in the maternal body. 
This suggests that high levels of this glycoprotein are associated with increased cytotoxic 
levels which could lead to severe cases of PE. CD69 expression on T-lymphocytes has also 
been observed to be up-regulated with increased severity of clinical symptoms of cardiac 
diseases (Hosono, de Boer et al. 2003). The role of this glycoprotein is not fully understood, 
yet several studies have involved CD69-expression to the down regulation of the immune 
response by promoting production of TGF-β within NK cells (Sancho, Gómez et al. 2005). 
Indicating that increase in CD69 in severe cases in the body’s way to control pathological 
condition. 
 
4.5. Limitations of the study 
One should note that a small amount of CD69 positive-NK cells has been isolated in healthy 
donors in the absent of any inflammation or disease (Lund, Boysen et al. 2012). This has been 
associated with the vaccination history and exercise program of the individual (Lund, Boysen 
et al. 2012). The CD69-expression on NK cells may also be influenced by the HIV treatment 
regimen. In this study all pregnant women received HAART and nevirapine. Therefore the use 
of CD69-expression on NK cells before the onset of maternal symptoms may lead to inaccurate 




This study employed a one-time point sample collection. It is important to establish a base-line 
for the CD69-expression on NK cells across all three gestational trimesters of normotensive 
uninfected pregnancies. This profile would enable comparisons between the aforementioned 







CONCLUSION AND RECOMMENDATIONS 
 
This study demonstrates an elevation in peripheral blood lymphocytes in patients with HIV-
associated PE. A neutralization of the immune response in HIV-associated PE has been 
previously suggested in other studies. However, the up-regulation in this study may be due to 
a modification of the functional profile of these cells, where the NK cell population augments 
cytotoxic amplification. More specifically, CD69-expressing pNK cells were elevated in PE 
compared to normotensive pregnancies. In PE the placenta is dysfunctional; therefore it is 
plausible to assume there is an inadequate release of factors that renders NK cells less 
cytotoxic. This suggests that high levels of the CD69-expressing NK cells are associated with 
increased cytotoxic levels which could lead to PE development. 
 
We propose that CD69-expressing NK cells have potential as a biomarker as an early 
diagnostic tool. Early identification of PE development is vital as PE is associated with 
diminished maternal and foetal morbidity and mortality. Additionally, being pre-eclamptic 
during pregnancy affects the quality of life post-partum. We also recommend better 
surveillance of maternal characteristics at antenatal booking to assess the risk of developing 
PE so that better management can be implemented in an attempt to save the lives of both the 




The actual physiological role of CD69 in immunity responses is still elusive and more research 
still needs to be done. Evaluating CD69-expressing NK cells across the three trimesters of 
gestation as well as a sub-stratification of lymphocyte count would be beneficial in 
understanding the role of CD69 in pregnancy. More importantly, an evaluation of the CD69 
glycoprotein in women <20 weeks gestation would validate the use of CD69 as risk 
indicator/biomarker for early identification of PE development. CD69 expression is triggered 
by several mechanisms, including other lymphocyte receptor and cytokine stimulation. Future 
studies should also concurrently evaluate CD69-expression on NK cells with T-cell receptors 
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Appendix IV: Preparation of reagents 
 
PBS + 0.1% Sodium Azide (Staining Buffer) 
PBS + 0.1% Sodium Azide buffer was prepared and kept at room temperature (± 24°C). 50ml 
of 10 X PBS solutions (Lanza BioWhittaker® PBS without Ca and Mg) and 0.5g of Sodium 
Azide (Whit eSa` sigma) were added into a measuring cylinder. The solution was then topped 
up to 500ml with de-ionized water (dH2O) and mixed thoroughly. In the final solution the 
concentration of the PBS was 1X and Sodium Azide was 0.1%. 
 
1X FACS Lysis solution 
1X FACS Lysis solution was prepared and kept at room temperature (± 24°C). 25ml of 10X 
BD FACS Lysis solution was added into a measuring cylinder, the solution was then topped 
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